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ABSTRACT
Mannose-binding lectin (MBL) is a circulating pattem-recognition molecule that recognizes 
microbial carbohydrate motifs leading to complement activation and cell lysis. Mutations in MBL 
promoter and exon-1 result in reduced protein levels and in a number of studies appear to increase 
susceptibility to infection. This thesis explores the role of MBL in paediatric infection in two 
clinical settings.
The effect of MBL deficiency on susceptibility and progression of HIV-1 infection was 
investigated in one hundred and twenty eight children, aged 2-16 years. MBL deficiency 
appeared to be less frequent in this population than in published series of Caucasian or African 
children. This may be due to selective survival of children with wild type MBL genotypes as 
patients with severe disease, as assessed by low CD4+T cell counts, were more likely to have 
MBL variant alleles. In support of this hypothesis, MBL deficiency was less frequent in children 
classified as long term non- progressors (LTNP-s).
A second study explored the impact of MBL on susceptibility and severity of infection in preterm 
neonates. One hundred sixty six preterm neonates were genotyped for MBL mutations by 
polymerase chain reaction (PCR) and heteroduplex analyses. Serum MBL levels were measured 
by ELISA. Comparison of genotypes (A= wild type, 0=variant alleles) and protein levels between 
groups was performed using Chi-square, Mann-Whitney or Kruskal-Wallis test. Low MBL levels 
were observed in premature neonates, particularly in the first week of life (p=0.001). MBL 
deficiency was associated with an increased risk of sepsis in VLBW neonates (<1500g), (p=0.01).
The studies described in this thesis provide support for MBL having a role in susceptibility to and 
severity of infection in children.
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CHAPTER 1
INTRODUCTION AND THESIS AIMS
1.1 MANNOSE BINDING LECTIN and INNATE IMMUNITY
Mannose-Binding Lectin (MBL) is a part of the humoral innate immune system. It is a 
pattem-recognition molecule able to detect a wide range of microbial and altered-self 
targets and recruit a number of host immune effector systems to clear those targets 
(Turner 1996). Profound genetic deficiency of MBL is common (less than 400 ng/ml) in 
-7-10% of the Caucasian population and appears to predispose individuals to a broad 
range of infectious diseases (Turner 1998; Turner and Hamvas 2000). Low-producing 
MBL-2 variants and low MBL levels are associated with increased susceptibility to and 
severity of a variety of infective illnesses, particularly when immunity is already 
compromised- for example, in infants and young children, patients with cystic fibrosis, 
and after chemotherapy and transplantation. The aim of studies presented in this thesis 
was to determine the potential role of MBL in susceptibility to bacterial infection in 
preterm neonates, and in Human Immunodeficiency Virus-1 (HIV-1) infection in 
children.
The innate immune system is our first line of defence against pathogenic micro­
organisms. All components of innate immunity are present prior to exposure to micro­
organisms. Our other major defence mechanism is the specific adaptive immune system 
which can take several days to mount an adequate response. In preterm neonates, 
immature adaptive response and the cellular effectors of innate response such as 
neutrophils, macrophages, dendritic cells and natural killer cells maybe reduced in 
number or may operate sub-optimally.
The innate immune system is being increasingly recognized as a central defence 
mechanism against infection (Janeway and Medzhitov, 2002). The early phases of the 
host response to infection depend on innate immunity in which a variety of innate 
resistance mechanisms recognize and respond to the presence of a pathogen. The innate 
immunity system composes cellular and humoral components which recognise the 
general features of microbes in order to clear these potentially damaging agents from 
body (Medzhitov and Janeway, 1997; Hoffmann et al, 1999). In contrast to the acquired 
immune system this does not require prior exposure to the infectious agent. One of the 
characteristic features of the innate immune system is microbial recognition. The 
specificity of the recognition systems employed is targeted against highly conserved 
structures common to large groups of microorganisms. This is achieved through 
interactions between host-derived pattern recognition receptors (PRR) and pathogen 
associated molecular patterns (PAMP) on microbes, which are frequently the repeating 
sugar arrays expressed on microbial surfaces (Janeway, 1989).
PRRs can be presented on the cell surface, in intracellular compartments, or secreted 
into the bloodstream and tissue fluids (Medzhitov and Janeway, 1997; Takeda and 
Akira, 2004). They are expressed on most effector cells of the immune system and, of 
particular relevance to innate immunity, is their presence on mucosal epithelia, 
macrophages, dendritic cells (DC) and neutrophils (Takeda and Akira, 2004).
The cell-surface PRRs include the well characterized membrane-bound toll-like 
receptors (TLR). The macrophage mannose receptor, is predominantly expressed by 
macrophages, but also by other cells such as dendritic cells, hepatic and lymphatic
endothelia. It functions as a PRR that mediate phagocytosis of microorganisms in the 
absence of opsonins, indicating that mannose receptor mediated lectin- phagocytosis 
maybe particularly important in anatomical spaces where opsonins maybe limited. Like 
MBL, macrophage mannose receptor is a member of the C-type lectin family and is 
closely related to Dectin-1 (Dendritic cell associated lectin-l)-an NK-like C-type lectin­
like, DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin) and DC-SIGNR 
(DC-SIGN-related) expressed on dentritic cells.
The main function of the macrophage mannose receptor is pathogen recognition and 
phagocytosis of microbial pathogens, delivery to lysosomal compartment where there 
are destroyed by lysosomal enzymes (Fraser et al, 1998). Other functions of MMR are 
clearance of endogenous ligands such as serum glycoproteins, lutropin, myeloperoxidase 
and thyroglobulin, and antigen presentation.
MBL, SP-A and D (surfactant protein A and D), C-reactive protein (CRP) and SAP 
(serum amyloid protein) are secreted pattern recognition molecules produced by the liver 
during the acute phase response in the early stages of an infection (Schwalbe et al, 
1992; Fraser et al, 1998). Secreted PRRs fiinction as opsonins by binding to microbial 
cell-walls and targeting them for recognition by the complement system and phagocytes 
(Medzhitov and Janeway 2000; Turner, 2003).
PAMPs include conserved structures such as Lipopolysaccharide (LPS), Peptidoglycan 
(PG) and flagellin which are found on most microoorganisms but not on host cells thus
allowing the immune system to distinguish “self’ from “non-self’ (Janeway, 1989; 
Medzhitov and Janeway, 2000; Takeda and Akira, 2004).
The role of MBL in susceptibility to infection is the subject of this thesis. For this 
purpose the structure and function of this critical secreted pattern recognition molecule 
(PRR) is discussed in greater detail below.
1.2 THE COMPLEMENT SYSTEM
Complement is an important system in the humoral innate response and is a major part 
of the human immune system that is responsible for defence against foreign particles and 
the clearance of immune complexes. Its actions “complement” the role of antibodies in 
the destruction of invading microorganisms. Complement protects against infection in 
three ways, 1) it generates large numbers of activated proteins which bind to pathogens, 
opsonising them for engulfment by phagocytes, 2) small fragments of some complement 
proteins act as chemoattractants to recruit more phagocytes to site of infection and 3) 
terminal components damage certain bacteria by creating pores in the bacteria through 
the generation of the membrane attack complex (MAC).
The complement system was first described in the 1890s as a heat labile protein in serum 
that “complemented” heat stable antibodies in the killing of bacteria. It is now known to 
be a highly developed host-defence system involved both in innate and antibody- 
mediated immunity (Walport, 2001a; Walport, 2001b). It consists of more than 30
plasma and cell surface protein components involved in a cascade of reactions. The 
formation of antibody and antigen complex induces conformational change in the Fc 
portion of the antibody molecule that exposes a binding site for Clq. Binding of Clq to 
Fc binding sites induces a conformational change in C lr that converts C lr to an active 
serine protease enzyme. C lr then cleaves Cls to its active form, which in turn activates 
C4 and C2 components. The resulting C4b2a complex is a C3 convertase, which 
converts the C3 proenzyme into the active enzyme C3a. This cascade leads to the 
cleavage of C3, a major (-concentration 1 mg/ml) serum protein. The above sequence of 
events is referred as the activation pathway (shown diagrammatically in Fig 1.1).
It is followed by the lytic pathway, during which the MAC is formed. As shown at 
figure 1.1 there are three distinct complement pathways of activation which depend on 
different molecules for their initiation but converge to generate the same set of effector 
molecules:
1) The Classical Pathway
2) Alternative Pathway
3) Lectin Pathway.
Figure 1.1 The complement system (taken from Presanis et al, 2003)
These three pathways all generate C3 convertase which leads to the generation of C3. 
The splitting of C3 produces a small C3a fragment and the larger C3b. Many 
interactions are possible at this point, but to progress towards cell lysis the classical and 
alternative pathway complexes, C4b2a and C3bBb, must covalently bind C3b. This 
results in new enzyme specificity-the C5 convertase. C3b forms a covalent dimer with 
the surface bound C4b or C3b of the C3 convertase. C5 binds to these dimers and is 
catalytically cleaved by the complex releasing the C5a anaphylatoxin and C5b, the first 
member of the terminal or lytic pathway. The alternative pathway is initiated by the 
covalent binding of a small amount of C3 to hydroxyl or amine groups on the cell-
surface molecules of microorganisms. This pathway also functions to amplify the 
activation of C3 (amplification loop). The lytic pathway essentially involves non- 
covalent binding of C5b to C6 and C7, producing a complex, C5b-7, which is 
hydrophobic in nature and can insert itself into lipid membrane. The binding of C8 
further enhances this process and leads to the polymeric assembly of C9 within the 
membrane. This MAC, C5b-9, causes lesions in the lipid membrane and results in cell 
lysis.
Defects in complement system are associated with a wide range of disease processes 
including susceptibility to infection, modulation of inflammatory processes and defects 
in regulation (Walport 2001a; Walport 2001b). Clinical implications of complement 
pathways deficiencies are summarized in Figure 1.2.
The clinical history of patients with classical pathway deficiencies varies slightly from
other complement-deficient patients. In the small number of patients studied, patients
with classical pathway deficiencies (i.e., deficiency of Clqrs, C2, or C4) are similar in
presentation to patients with primary immunoglobulin deficiencies. For example,
patients tend to have frequent sino-pulmonary infections with organisms such as 
e
Streptococcus pneumoniae or Hemophilus influnzae. More commonly, these patients 
develop autoimmune syndromes. One of the primary clinical manifestations of patients 
with deficiencies of classical pathway components is immune complex disease.
The C3 component occupies an important place at the junction of both the classic and 
alternative pathways. As such, C3 deficiency results in severe opsonization dysfunction.
C3 deficiency also causes deficient leukocyte chemotaxis because of decreased C3a 
concentrations and decreased bactericidal killing secondary to decreased formation of 
membrane-attack complex (MAC). Patients with C3 deficiency develop severe episodes 
of recurrent pneumonia, meningitis, peritonitis, or sepsis. The most common pathogens 
are Streptococcus pneumoniae, N  meningitidis, Haemophilus influenzae, and 
Staphylococcus aureus. In addition to opsonization problems, C3 deficiency also impairs 
adequate clearance of circulating immune complexes, and 79% of patients with C3 
deficiency develop some form of collagen vascular disease. The inherited deficiency of 
the MAC causes bacterial infection, particularly Neisserial infections.
Figure 1.2 The clinical implications of complement pathways deficiencies (from 
eMedicine)
Deficiency states maybe be acquired or inherited. Acquired defects are relatively 
common, maybe acute or chronic and are frequently reversible with treatment of the 
disease responsible for the defect. Infection is an uncommon complication of acutely 
acquired defects but is a well recognized component of chronic deficiency states. 
Acquired defects are classified according to the mechanism responsible for the defect: 
consumptive, synthetic, or catabolic. Immune complex disease, vasculitis, and C3 
nephritic factor are examples of conditions in which complement activity is low as a 
result of consumption. Decreased synthesis is most commonly observed in patients with 
severe liver diseases. Accelerated catabolism of complement proteins occurs in patients 
with protein loosing enteropathies or the nephritic syndrome. Hereditary complement 
deficiencies are uncommon (about 0.03% prevalence) in the general population. 
Homozygous C2 deficiency appears to be the most common inherited defects.
1.2.1 The lectin pathway of complement activation
The lectin pathway was discovered in 1989 (Super et al, 1989). This pathway involves 
carbohydrate recognition on microbial surfaces by pattern recognition molecule, such as 
MBL, independently of specific antibody. MBL is an important component of innate 
immunity and is a central recognition molecule of the lectin pathway of complement. 
MBL is a member of the Collectin family of proteins which are characterized by the 
presence of a collagenous region and C-type lectin carbohydrate recognition domain 
(CRD), (Malhorta et a l, 1994; Turner, 2003; van de Wetering et al, 2004). It is an 
acute phase protein of hepatic origin. MBL binds to repeating sugar arrays on microbial 
surfaces including Gram-positive and Gram-negative bacteria, to fungal species, some
10
viruses and also to protozoa and other parasites (Table 1.1; Kilpatrick 2002; Jack and 
Turner, 2003, Shang et al, 2005).
Tablel.l MBL binding to micro-organisms. Data from various studies have been 
included (copied from Kilpatrick 2002).
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MBL functions as an opsonin and its biological effect is mediated by direct killing via 
complement through MAC or by promoting phagocytosis either by the lectin pathway of 
complement or by direct binding to one or more cell surface receptors (Turner 1996; 
Neth et al., 2000; Gadjeva et al, 2004b).
The lectin pathway also comprises three MBL associated serine proteases, MASP-1, -2, 
-3 and MApl9/ sMAP, a small MBL associated protein with no serine protease activity 
(Stover et a l, 1999; Dahl et al, 2001). The MASPs are homologous to the Clq- 
associated proteases, C lr and Cls. MBL therefore activates complement by a 
mechanism very similar to Clq, and engages the opsonic activity of complement to clear 
micro-organisms. MASP-2 is a homologue of Cls of the classical complement pathway 
and is responsible for the activation of C4 and C2. When MBL associated with MASP-2 
binds to sugar arrays on the surface of microbes, the MBL-MASP-2 pro-enzyme is 
activated and sequentially cleaves C4 and C2 thereby generating the C4bC2a complex, a 
potent C3 convertase (Thiel et a l, 1997; Matsushita and Fujita, 2001). C4b2a cleaves C3 
and generates multiple C3b fragments which bind covalently to the surface of 
microorganisms and acts as a key opsonin. These fragments are recognized by the CRl 
(CD35) receptor of phagocytes. Some C3b is converted to iC3b which is recognised by 
CR3 receptors. The C3b fragment also facilitates activity of C5 convertase. Cleavage of 
C5 produces the anaphylatoxin C5a, and the C5b fragment initiates formation of the 
MAC causing direct lysis of the inciting pathogen (Figure 1.2).
MBL isolated from serum is apparently only associated with MASP-1 and MASP-2 and 
not C lr or Cls (Thiel et al, 1997). It has been reported that MASP-1 is able to cleave
12
C3 directly (Matsushita et al, 2000; Dahl et al., 2001; Rossi et al, 2001). Work with 
recombinant and purified native MASP-1 shows that direct C3 cleavage by this protease 
is very slow and may not be biologically significant (Rossi et al, 2001). MASP-1 does 
not appear to have a role in activating MASP-2, and has very limited or negligible 
activity towards other complement proteins. Recently, a third MASP (MASP-3), which 
is generated by alternative splicing of MASP-1, was reported to be associated with MBL 
but its function and also that of MApl9 is presently unknown, although MASP-3 may 
compete with MASP-2 for binding to MBL (Dahl et al., 2001).
The lectin pathway is also known to be activated by human serum ficolins; L-ficolin and 
H-ficolin (Matsushita and Fujita, 2002; Holmskov et al, 2003; Lynch et al, 2004) and 
by M-ficolin, a secretory protein (Liu et al, 2005). The ficolins comprise a collagen- 
and fibrinogen like domains (Matsushita and Fujita, 2001; Fujita, 2002), (Figure 1.3). 
They also bind to bacteria in association with MASPs and small MBL-associated protein 
(sMAP) and are believed to have complementary and overlapping microbial specificities 
with MBL (Matsushita and Fujita, 2002).
1.3 MBL SYNTHESIS, STRUCTURE and FUNCTION
MBL was first isolated and cloned from hepatocytes, and the liver is considered to be 
the principal site of MBL synthesis (Summerfield and Taylor, 1986). Subsequent studies 
confirmed that MBL is produced by hepatocytes and secreted into the bloodstream 
(Ezekowitz et al, 1988; Taylor et al, 1989; Sastry et al, 1989). MBL has also been
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found in body fluids, including nosopharyngeal secretions, middle ear effusions, ascites, 
urine, cerebrospinal fluid (CSF), amniotic fluid and synovial fluid (Garred et a l, 1993; 
Terai et a l, 1993). Two studies have assessed MBL production in advanced in liver 
disease (Ryley et al, 1993; Homann et al, 1995). The first found that in chronic liver 
disease, stainable liver MBL did not correlate with serum MBL levels (Ryley et al, 
1993). The second study showed that serum MBL was significantly elevated in patients 
with cirrhosis (Homann et al, 1995). These observations may suggest that there is extra- 
hepatic contribution to serum MBL. Experimental data support the concept of non- 
hepatic MBL synthesis. Human monocytes and monocyte-derived dendritic cells are 
both capable of synthesizing MBL in vitro (Downing et al, 2003). Several rodent 
studies have also demonstrated extra-hepatic expression of MBL, with the sites 
responsible including small intestine, kidney, as well as lymphoid and myeloid cells 
(Morio et al, 1997; Uemura et al, 2002; Wagner et al, 2003). Studies on MBL 
secretion from rat hepatocytes suggest that the protein is synthesised in the endoplasmic 
reticulum before transportation to the golgi apparatus prior to secretion. The half-life (T 
1/, ) of secretion is 4 hours, which is long compared to other hepatocyte secretory proteins 
(e.g.T 1/,= 1 hour for albumin). Once in circulation, serum MBL turnover is relatively fast 
with a T ^ of 1.6 days when compared with other serum proteins (~3 days).
The human MBL monomer is 32kD in size and composed of 208 amino-acids 
(Kawasaki et al, 1983; Summerfield and Taylor, 1986; Taylor et a l, 1989; Sastry et al, 
1989). MBL peptide contains an N-terminal region of 21 amino acids followed by the 
collagenous region which consists of 19 glycine-X-Y repeats (where X and Y can be any 
amino-acid) with an interruption of this pattern at repeat 8 (Taylor et al, 1989, Sastry et
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al., 1989). In human MBL, a neck region (residues 88-113) connects to the calcium 
dependant CRD which recognizes repetitive oligosaccharide moieties present on a wide 
array of pathogens (Figure 1.3 a; Sheriff et al, 1994).
Figure 1.3 Diagram showing the single MBL peptide (A), basic structural sub-unit 
(B), and oligomeric structure of MBL (the hexametric form) (C), (modified from 
Fujita et al, 2004).
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The basic structural unit of MBL is a homotrimer of MBL peptides (sub-units) that self 
associate into a collagen-like triple helix (structural unit, Figure 1.3 b). This structural 
unit oligomerises into high order structures such as tetramers, pentamers and hexamers 
(Figure 1.3 c).
Functional MBL circulates as higher order multimers. The higher order structure allows 
high-affinity interaction between MBL lectin domains and microbial oligosaccharides, 
resulting in conformational change of the MBL multimer and activation of associated 
molecules, MASPs leading to complement activation.
The serum levels of the human MBL are regulated in serum so that any one person 
displays a phenotype of low, intermediate, or high levels. There is a close relationship 
between circulating MBL and distinct genotypes. A comprehensive study by Minchinton 
and colleagues showed the correlation between MBL genotype and protein levels 
(Figure 1.4), (Minchinton et al, 2002). Humans exhibit a 1000-fold variation in 
circulating MBL from <0.01 to 5 pg/ml or more.
Genotype has the largest influence on circulating MBL levels but non-genetic influences 
are also important. MBL is constitutively expressed but serum levels can increase up to 
threefold during an acute phase response, after surgery or infection (Thiel et al, 1992).
The gene encoding MBL, MBL-2, contains several common polymorphisms that 
influence transcription and disrupt assembly of the molecule, in particular distorting the 
collagenous helix and impairing polymerisation to higher order functional multimers
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(Larsen et al, 2004). Although high and low molecular-mass forms of MBL can be 
detected in serum, studies have shown that it is only higher order oligomers that are able 
to confer function such as binding to microorganisms and activation of complement 
(Larsen et al, 2004).
Figure 1.4 Correlation between MBL levels and genotypes. Genotypes are in a 
simplified form, A/A indicates wild type excluding XA/XA; A/0 indicates 
heterozygotes including XA/XA; 0 /0  indicates homozygote mutants and compound 
heterozygote mutants (Minchinton et al, 2002).
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MBL gene transcription can be modulated by interleukin (IL-6) and dexamethasone as 
observed in human hepatoma cell lines (Arai et al, 1993). IL-6, dexamethosone 
increased MBL gene expression in this cell line. Interestingly, IL-1 inhibited 
transcription whereas TNF-a and INFy had no effect (Arai et al, 1993).
Another study was able to detect low levels of MBL mRNA in the HepG2 cell line 
(Ezekowitz et al, 1988). MBL levels may also be influenced by different hormones in 
vivo (Sorensen et al, 2006). The recent study by Sorensen and co-workers suggested 
that growth hormone (GH), interleukin (IL-6) and thyroid hormones (T3 or T4) 
significantly increased MBL synthesis in a dose-manner (Sorensen et al, 2006).
1.4 MBL GENE STRUCTURE
Human MBL is encoded by the MBL-2 gene on chromosome lOqll.3 (Sastry et al, 
1989 and Taylor et al, 1989). The intron / exon structure of the 7 kb human gene has 
four exons. These regions comprise an N-terminal cysteine-rich domain (exon 1), a 
collagen region (exons 1 and 2), followed by an a-helical neck region (exon 3). The C- 
terminal encodes for the carbohydrate recognition domain (exon 4) (Taylor et al, 1989). 
A schematic representation of the MBL gene organisation is shown in Figure 1.5.
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Figure 1.5 Human MBL 2 gene structure and the MBL mutations (modified fiom 
Larsen et al., 2004).
At the top naturally occurring mutations MBL-B, -C, and -D are highlighted.
Below is the wild-type (WT MBL-A) protein sequence of the collagen region of MBL. 
The various protein domains of the single polypeptide chain of MBL: the cysteine rich 
N-terminal, the collagenous region (snaking line), the a helical coiled-coil region, and 
the CRD are shown schematically.
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Several studies have now shown that the level of MBL in blood is influenced by the 
presence of single nucleotide polymorphisms (SNPs) in the MBL-2 gene (Madsen et al, 
1995; 1998). Three missense mutations in exon 1 at codons 52, 54, and 57 encode for 
variant alleles termed as D, B, and C, respectively, reflecting the order of their discovery 
(Lipscome et al, 1992; Turner 2003). The presence of any of these coding mutations is 
represented by “O”. By convention, a wild-type coding region is termed the “A” allele. 
A point mutation at base 230 of exon 1 of the MBL-2 gene changes codon 54 (allele B) 
from GGC to GAC resulting in amino-acid substitution from a glycine to a much larger 
(in size) aspartic acid in the collagen region. Similarly, a point mutation in codon 57 
(allele C) results in a glutamic acid residue instead of a conserved glycine (Lipscombe et 
al, 1992). A third structural gene mutation in codon 52 (D allele) was described in 1994 
(Madsen et al, 1994). This change results in arginine being substituted by a cysteine 
residue. This mutation appears to have a less severe effect on the levels of circulating 
MBL when compared to allele B and C (Madsen et al, 1994).
Studies of different ethnic groups indicate that the prevalent haplotypes that specify 
high, intermediate, low or undetectable levels of MBL in serum vary considerably 
(Lipscombe et al, 1992; Madsen et al, 1994; Madsen et al, 1995; Lipscombe et al, 
1996; Mead et al, 1997; Madsen et al, 1998; Turner et al, 2000(a); Minchinton et al, 
2002). MBL-2 coding alleles associated with low blood levels are present in up to 40% 
of Caucasoids, with up to 8% having genotypes associated with profound reduction in 
circulating MBL levels. The frequencies of the coding mutations studied in various 
population groups are listed in Table 1.2.
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Table 1.2 Frequency of exon-1 mutations found in the human MBL gene amongst 
different population groups (according to Lipscombe et al, 1992).
The codon 54 mutation has been identified in a range of European and Asian 
populations at a frequency of 0.13-0.16 (Lipscombe et al, 1992; Garred et al, 1992; 
Madsen et al, 1994) and the codon 57 mutation occurs in most Sub-Saharan African 
populations at even higher frequencies: 0.23-0.29 (Lipscombe et a l, 1992 and 1996; 
Garred et al, 1992; Madsen et al, 1994). The codon 52 mutation occurs at much lower 
frequencies (0.06 or less) both in African and non- African populations.
Serum MBL levels, however, vary substantially within each coding genotype. 
Additional polymorphisms in the promoter and 5’-untranslated regions of the MBL-2 
gene have a modulatory effect on basal MBL protein levels (Madsen et al, 1995; Garred 
et al, 2003a). Single nucleotide substitutions are present in the promoter region at
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position -550 (G—C, alleles “H” and “L”); position -221 (G -^C, alleles “X” and “Y”); 
and at nucleotide +4 of the 5’-untranslated region (C-^T, alleles “P” and “Q”). The -550 
(H/ L), -221 (X/ Y), +4 (?/ Q) promoter region polymorphisms occur in one of the 
following linkage haplotypes HYP, LYQ, LYP or LXP; superimposing very high, high, 
medium and low levels onto the exon-1 genotype respectively (Madsen et al, 1995; 
Madsen et a l, 1998). One of these variants (X/ Y) profoundly influences expression of 
the MBL. There is also linkage disequilibrium between the structural and promoter 
mutations such that a B allele is always linked to an LYP promoter genotype, a C allele 
to an LYQ promoter genotype and a D allele to an HYP promoter genotype (Lipscombe 
et al, 1996). The wild-type genotype (A/A) is found in association with four promoter 
haplotypes.
1.5 MBL and HOST DEFENCE
1.5.1 The role of MBL in opsonization and phagocytosis
MBL may also interact directly with cell surface receptors and thereby promote 
opsonophagocytosis and modify cellular activation. This property was first reported by 
Kuhlman et al, (1989) in a study of MBL coated Salmonella enterica serovar 
Montevideo organisms. MBL opsonized Salmonella enterica directly without the 
involvement of the complement system (Kuhlman et al, 1989). In another studies, the 
phagocytosis of Cryptococcus neoformans or Mycobacteruim avium was significantly 
enhanced by recombinant MBL (Levitz et a l, 1993; Polotsky et al, 1997). 
Subsequently, a number of putative MBL binding proteins/ receptors have been
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proposed including cClqR/ calreticulin (Malhotra et al, 1994; Stuart et al, 1997), 
ClqRp/ CD93 (Tenner et al, 1995; Steinberger et al, 2002) and CRl/ CD35 (Ghiran et 
al, 2000). The recent study by Neth and co-workers showed that MBL-MASP 
complexes can promote opsonophagocytosis of Staphylococcus aureus independently of 
complement activation (Neth et al, 2002). However, it is unclear whether MBL is acting 
as a direct opsonin for microorganisms (Kuhlman et al, 1989; Polotsky et al, 1997) or 
is enhancing other pathways such as complement - (CRl) or immunoglobulin - (Ig) 
receptor mediated phagocytosis (Tenner et al, 1995; Ghiran et al, 2000). Indeed, it is 
still unclear whether MBL receptors are distinct from receptors for the structurally 
similar Clq molecule (Bajtay et al, 2000).
1.5.2 MBL and inflammation
MBL has also been proposed to display anti-inflammatory properties by modulating the 
cytokine production by monocytes. Addition of low levels of MBL to whole blood 
resulted in increases of TNF- a, IL-1 p and IL-6 production, whereas higher doses of 
MBL suppressed the production of all three inflammatory cytokines (Jack et al, 2001, 
Turner 2003). It has also been found that MBL binds to apoptotic cells and stimulates 
their ingestion by phagocytes (Ogden et al, 2001).
1.5.3 The common opsonic defect and MBL deficiency
The common opsonic defect and eventually MBL deficiency was first reported in 1968 
when Miller et al described the case of a child, who had suffered from recurrent upper 
respiratory tract infections, diarrhoea and failure to thrive in the first two years of life
23
(Jacobs and Miller, 1972). The patient did not appear to have a deficiency of 
immunoglobulin but, in the presence of the patient’s serum neutrophils fi*om human 
donors were unable to phagocytose Saccharomyces cerevisiae (Baker’s yeast) 
efficiently. The patient’s neutrophils were able to phagocytose efficiently when the 
serum of other donors was used in the same assay. There was a familial association of 
the opsonic defect, although the other family members were healthy. The patient was 
treated with plasma infusions, which ameliorated the condition. Further studies showed 
the abnormality was present in approximately 5-8% of the general population (Soothill 
and Harvey 1976; Levinsky et al., 1978). The frequency of this defect was higher in 
recurrent unexplained infections, but the defect was also present in healthy adults with 
no history of persistent infection.
In the early 1980’s, it was known that the complement system is activated by two or 
more immunoglobulin G molecules or one IgM molecule bound to a target surface 
(classical pathway) or by the binding of hydrolysed C3 to a permissive surface such as a 
bacterium (alternative pathway). Activation in this manner would lead to opsonisation of 
the target by the amplified deposition of multiple opsonic C3 fragments or the direct 
lysis of Gram negative bacteria by formation of macromolecular complex, MAC 
(Walport et al., 2001). Since a gross immunoglobulin defect did not appear to be cause 
of the opsonic defect, and in any case would be unlikely in such a large proportion of the 
population, a study of complement deposition was begun. Biochemical assays using the 
D-mannose polymer zymosan confirmed that the absence of a serum factor led to the 
poor deposition of C3b and iC3b on the yeast surface (Turner et al, 1981) without
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deficiency of any known component of either the alternative or classical pathways of 
complement activation (Turner et al, 1991).
MBL appeared to be an ideal a candidate molecule for the serum factor deficient in 
patients with the common opsonic defect. It was demonstrated these individuals were 
deficient in MBL and that the addition of purified MBL to the serum of these patients 
resulted in increased deposition of C3b, Factor B and C4 on zymosan (Super et al, 
1989).
When mannan, a predominant polysaccharide in zymosan, was used in complement 
binding assays to study a population of blood donors, defective opsonisation was 
associated with low levels of MBL and the role of the novel lectin pathway of 
complement activation was established (Super et a l, 1989; 1990). The importance of a 
newly recognised complement defect was detailed by Turner and co-workers (Turner et 
al, 1991).
1.6 THE ROLE OF MBL IN INFECTIOUS DISEASE
1.6.1 Disease model of MBL deficiency- MBL mouse knock-out models
To evaluate a causal role of MBL in host susceptibility to infection mouse models of 
MBL deficiency were created. Although human MBL deficiency was first report in 
1989, the existence of two functional genes in rodents- mbl-1 and mbl-2 that encode for 
MBL-A and MBL-C, respectively delayed the generation of MBL-deficient animals.
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These two forms of rodent MBL bear 50 % homology to one another and are both able 
to activate MBL-MASP pathway (Liu et al, 2001). The generation of double knock-out 
(DKO) MBL deficient mice was recently reported (Shi et al, 2004, Takahashi et a l, 
2006). The authors found 100% of MBL-null mice died 48 hours after exposure to an 
intravenous inoculation of Staphylococcus aureus compared with 55% mortality in wild- 
type mice. Importantly, pre-treatment of MBL-null mice with recombinant human MBL 
(rhMBL) restored MBL-MASP pathway in vivo. This study provides evidence that the 
presence of low-producing MBL-2 gene haplotypes might be a genetic factor that 
predisposes certain humans to poor outcomes as a result of S. aureus infection.
To study the effects of MBL deficiency during viral infection a model of generalized 
herpes simplex virus -2 (HSV-2) infection was chosen (Gadjeva et al, 2004a). MBL-A 
and MBL-C DKO mice was infected with HSV-2 via the intraperitoneal route. DKO 
mice cleared HSV-2 from the liver less effectively than the comparable wild-type 
animals. Reconstitution with rhMBL before and during the HSV-2 infection dramatically 
reduced the viral titres in the liver. The data showed that MBL modulates the response to 
HSV-2 in mice by affecting neutralization of the virus. This suggests that lack of MBL- 
mediated complement activation increases susceptibility to viral infection.
These results provide in vivo evidence that MBL plays role in first line host defense 
against infection with S .aureus and HSV-2 and support the clinical associations between 
MBL deficiency and increased susceptibility to certain infections.
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1.6.2 The human studies-the role of MBL in health and disease
MBL deficiency has been genetically defined as possession of haplotype associated with 
decreased levels, which applies to ~ 40% of the population (Madsen et al, 1994; 
Madsen et al, 1995). Profound MBL deficiency (<400 ng/ml) occurs in -7-10 % of the 
Caucasian population (Turner, 1998). MBL deficiency is thought to be one of the most 
common immunodeficiencies. The fact that most MBL deficient people do not get 
infectious has led to speculation that a second immune defect needs to be present to 
render the individual susceptible to infection. In support of an earlier suggestion, 
Aittoniemi and co-workers found that MBL deficiency only presented clinically when 
there was an associated immunodeficiency such as IgG subclass deficit (Aittoniemi et 
al, 1998). There is evidence that severe infections were more common in patients with 
combined deficiencies, either IgA or any of the IgG subclasses or IgA and MBL 
deficiency (Santaella et al, 2005).
The impact of MBL deficiency on the wellbeing of the general population has been 
questioned recently. In 2003, Tacx et a l investigated 177 unselected adults hospitalised 
with fever. They found microbial infection induced complement activation 
independently of MBL and concluded that MBL deficiency does not predispose to 
serious infection in unselected adults (Tacx et al, 2003). The impact of variant MBL 
haplotypes among the general population was also questioned in the recent study 
involving 9245 Danish adults. The authors found no significant difference in morbidity 
and mortality in MBL deficient individuals versus controls (Dahl et al, 2004). Studies 
by Ross et a l offered one potential explanation for these observations. They found that
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antibody-mediated activation of the classical pathway of complement compensated for 
impaired target opsonization via the MBL pathway in MBL deficient individuals (Ross 
et al, 2004). These studies further confirm that MBL deficiency may only becomes 
clinically relevant when it occurs in combination with defects in other arms of immune 
system.
The high frequency of MBL deficiency in the general population suggests that defective 
MBL mediated immunity can be compensated by alternative defence strategies. This is 
not true of deficiencies of some immune components. For examples, patients with X- 
linked agammaglobulinaemia suffer from severe and repeated bacterial infections, 
particularly those caused by encapsulated organisms. It would appear that MBL 
deficiency may not be as important as some other immune components, because 
alternative means of eradicating pathogens have evolved. For example there are many 
ways to kill bacteria. Immunoglobulin, independently and in association with the 
complement system, can effectively destroy bacteria in the absence of MBL. While 
MBL may enhance opsonisation, is not absolutely required.
The role of MBL in disease was first appreciated within paediatric population and the 
most rigorous MBL clinical research has been conducted in this group. Low serum MBL 
and MBL-2 mutations have been implicated in childhood infection. This association has 
been demonstrated in children with mild respiratory tract infections managed within 
community (Koch et al, 2001), in more severe infections requiring hospital admission 
(Summerfield et al, 1997), as well as in the paediatric intensive care unit setting where
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MBL deficiency was associated with a greater risk of developing the Systemic 
Inflammatory Response Syndrome (SIRS), (Fidler et al, 2004).
The time during which MBL is most relevant for protection against infection is probably 
infancy and early childhood. The hospital based study found a significant association 
throughout childhood (0 to 18 years of age), (Summerfield et al, 1997), whereas in the 
community based-study the influence of MBL deficiency was strongest in children 
between 6 and 17 months of age (Koch et al, 2001). This later study showed a greater 
risk of infection in MBL deficient infants, at a time when passively acquired maternal 
immunity has waned but adaptive antibody responses are still immature (time of 
transient hypogammaglobulinaemia of infancy). This has led to the concept of a 
“window of vulnerability”, whereby the importance of MBL in host defence is greatest 
when adaptive immune responses are deficient.
Another area of uncertainty concerns the precise level of MBL that confers protection, 
and below which children are at risk. Early studies using the functional opsonisation 
assay identified 5-10 % of the population as deficient and therefore at risk; this 
corresponds to a protein level of <100 ng/ml (Soothill and Harvey 1976; Levinsky et al., 
1978). Garred et a l (1995) found only homozygotes for structural alleles to be at risk; 
the corresponding protein concentration was < 20 ng/ml (Garred et al, 1995). Another 
study, however, has been reported that heterozygotes to be at risk as well (Summerfield 
et al, 1997). It has been shown that MBL levels in the heterozygote group range from 
nil to 1.2 pg/ml, thus providing a range of protection in individuals.
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1.7 MBL and SUSCEPTIBILITY TO INFECTION
The role of MBL in increased susceptibility to various bacterial, viral and fungal 
infections has been studied in both paediatric and adult populations (Summerfield et al, 
1997; Turner et al, 2000; Kilpatrick et al, 2002; Eisen et al, 2003). MBL deficiency 
has been implicated in both disease susceptibility and as a modulator of severity:
- Chronic hepatitis B (Thomas et al, 1996; Yuen et al, 1999),
- Chronic hepatitis C (Matsushita et al, 1998),
- HIV infection (Garred et al, 1997),
- Plasmodium falciparum (Luty et al, 1998),
- Meningococcal infection (Hibberd et al, 1999),
- Cystic fibrosis (Garred et al, 1999; Gabolde et al, 2001; Davies et al, 2004),
- Cryptosporidium parvum (Kelly et al, 2000),
- Visceral Leishmaniasis ( Santos et al, 2001),
- Systemic Inflammatory Response Syndrome (SIRS) in adults (Garred et a l 2003)
- SIRS in children (Fidler et al, 2004),
- HSV-2 (Gadjeva et al, 2004).
Interestingly, MBL deficiency has also been suggested to have a protective effect against 
certain diseases in populations where variant alleles are frequently observed (Santos et 
al, 2001).
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An association between MBL deficiency, poor lung function and shortened life span in 
cystic fibrosis (CF) patients was reported, and presumed to be connected with severity of 
pulmonary infections P. aeruginosa, B. cepacia (Garred et al, 1999; Gabolde et al, 
2001). Thus, MBL has been identified as a modifier of severity in cystic fibrosis (CF), 
although studies have produced differing results and the mechanism of action remains 
(Aittoniemi et al, 1996) unclear. A recent study (Davies et al, 2004) involving large 
cohort of adults and children has explored this relationship further. Adults with two 
structural mutations, but not heterozygotes, had significantly reduced lung function and 
oxygen saturations, more frequent hospital admissions and raised systemic inflammatory 
markers. This observation was not related to increased rates of infection with P. 
aeruginosa, and there was no increased susceptibility to B.cepacia. Interestingly, none 
of these findings were mirrored in the paediatric cohort. Severe MBL deficiency appears 
to be detrimental to CF adults, although heterozygotes are not affected. Different results 
were obtained from paediatric cohorts. The group of homozygotes was very small (n=6) 
and the study was probably underpowered to detect a difference. Garred et al, (1999) 
observed an MBL effect in individuals as young as 8 years old, in contrast most of the 
children in the Davies et al study had well-preserved lung function, and low or 
undetectable levels of systemic inflammatory markers (C-reactive protein (CRP), white 
cell counts).
MBL variant alleles were associated with an increased risk of developing sepsis, severe 
sepsis, septic shock and death in adults (Garred et al, 2003). Further, Fidler and co­
workers reported that MBL variant alleles were associated with an increased risk of 
developing Systemic Inflammatory Response Syndrome (SIRS) and of progression to 
sepsis and septic shock in children (Fidler et al, 2004).
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1.7.1 Changes in serum MBL levels with age
Terai et al, 1993 studied a total of 1085 normal Japanese sera from individuals ranging 
in age from 3 to 100 years old were measured for MBL levels (Terai et al, 1993). A 
high age dependency in serum MBL levels was observed. MBL levels declined from age 
group 3-9 to 20-29 years old, but remained constant after 30-39 years old. Thus, MBL 
levels of the younger groups (less than 20 years old) were apparently higher that those of 
the older (more than 20). Aittoniemi and colleagues investigated the changes occurring 
in the serum of MBL in infancy, during later childhood and in adults. The serum 
concentration of MBL increased significantly after birth, and was at it’s highest (the 
mean 8.13 mg/L) at the age of 1 month. After that, it declined to the initial level until the 
age of 5 months. The MBL levels continued to decrease during childhood, and after the 
age of 12 years the MBL values reached the adult level (Aittoniemi et al, 1996). In a 
study by Kilpatrick et al, (1996) measured MBL concentration in 237 umbilical cord 
blood samples and compared to adults controls consisted of sera prepared from 
consecutive blood donations (n=352), (Kilpatrick et al, 1996). MBL levels in cord 
blood samples were found to be significantly lower than those of blood donors. 
Therefore, it should be stressed that age has to be taken into consideration in the 
evaluation of MBL levels.
1.7.2 Changes in serum MBL levels in early life
Determination of MBL levels in children (less than 3 years old), including neonates, 
have been carried out (Terai et al, 1993; Thiel et a l, 1995; Lau et al, 1995; Frakking et 
al, 2006), in order to determine how and when the MBL levels change during early life.
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Terai and co-workers have studied perinatal changes in serum MBL levels, from day 0 
to day 5 in term neonates (Terai et al, 1993). A considerable amount of MBL is present 
in serum at birth and it has been observed an increase in MBL levels after birth during 
the first 5 days of life. The serum MBL in term neonates reaches its highest level within 
the first week after birth (2.48 pg/ml) when levels are almost equal to that observed in 
an older (3-9 year) study group (Terai et a l, 1993). In a study by Thiel and co-workers 
MBL levels were measured in term neonates through the first 12 months of life (Thiel et 
al, 1995). It has been reported that levels of MBL increase during the first 3 months of 
life to achieve levels comparable to that observed in adults (Thiel et al, 1995). On 
average, the level of MBL at term was 37% of the post 3-month level. They also showed 
that in premature neonates, MBL levels increased 3-fold from the time of birth until the 
10th week of life. According to Aittoniemi et al, MBL concentration increased 
significantly after birth with highest levels detected at 1st month of age (Aittoniemi et 
al, 1996). Then, the MBL concentration declined to the initial level until the age of 5 
months.
To date, only a few studies have investigated MBL levels as a function of gestational 
age in preterm neonates (Malhorta et al, 1994; Lau et al, 1995; Hilgendorff et al, 2005; 
Frakking et al, 2006). Malhotra and co-workers measured MBL levels in amniotic fluid 
samples obtained vaginally in patients with ruptured membranes following the 
spontaneous onset of labour (Malhotra et al, 1994). Patients’ gestational age ranged 
from 26 to 41 weeks of gestation. Interestingly, Malhotra et al, found a sharp increase in 
MBL levels in the amniotic fluid at approximately 32 weeks of gestation, suggesting 
MBL may play a role in the antibody-independent recognition and clearance of
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pathogens in the amniotic cavity, thus providing protection to the foetus in the amniotic 
cavity from ascending vaginal infection, particularly towards term.
A large study to determine the developmental profile of MBL in preterm neonates was 
performed by Lau and co-workers (Lau et al, 1995). MBL was measured in 885 
longitudinally collected serum samples from 168 preterm neonates, and 63 were 
genotyped for the codon 54 mutation. They postulated that there is a maturation process 
in MBL levels for those without the codon 54 mutation from preterm to term neonates 
and to adults. However, for those with the codon 54 mutation, there was a significant 
difference in MBL levels between preterm and term neonates, but not between term 
neonates and adults. This observation suggests that the maturation process for MBL 
levels for those preterm infants with the codon 54 mutation is probably completed by 
full-term gestation. The two recently published studies confirmed that preterm neonates 
are MBL deficient at birth compared to term neonates and MBL levels increase with 
gestational age (Hilgendorff et al, 2005; Frakking et al, 2006). Summary of studies on 
MBL in early life are summarized in Table 4.2 (Chapter 4).
1.7.3 MBL and infection in early childhood
There are two hypotheses regarding the role of MBL in natural immunity and infection. 
The so-called “ante-antibody” concept proposed by Ezekowitz envisages a role
immediately following primary contact with any organism during the days before the 
first antibody appears (Ezekowitz et al, 1988). The alternative hypothesis argues for a 
major role during the “window of vulnerability” experienced by all infants following the
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decline in levels passively acquired maternal antibodies and preceding the maturation of 
the infant’s own antibody repertoire (Super et al, 1989; Turner et al, 1991).
Kilpatrick et al, (1998) found that MBL may be important for innate immunity and in 
some cases of sudden infant death syndrome (SIDS) where bacterial infection may have 
contributed to SIDS. Therefore, relative MBL deficiency might be associated with 
susceptibility to SIDS. The proportion of infants with low MBL values was similar in 
SIDS infants and controls. However, the mean MBL levels for the SIDS group were 
higher than that of the controls. This difference could be interpreted as an acute phase 
response (Kilpatrick et al, 1998).
Kielgast et al, 2003 investigated whether MBL in umbilical cord blood (UCB) is 
associated with incidence rate of hospitalizations for infections during early childhood. 
It was a follow-up study fi*om birth to 31 months of age. A total of 2104 infants were 
enrolled. Rate of hospitalization with infections in children with low levels of MBL was 
similar to hospitalization because of other diseases. Low levels of MBL in UCB were 
associated with hospitalization in general and particularly with hospitalization for viral 
infections (Kielgast et al, 2003). Other hospital based-studies carried by Koch et al 
(2001) have found that increased susceptibility to acute respiratory tract infections 
(ARIs) in children below 2 years of age is associated with low levels of MBL. A 2.08- 
fold increased relative risk of ARI was largely restricted to children aged 6 to 17 months 
while the effect amongst 0-5 month age was minimal. This suggests that genetic factors 
such as MBL deficiency may play an important role particularly during the vulnerable 
period of childhood when the adaptive immune system is immature.
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1.8 AIMS OF THIS THESIS
A major aim of this thesis is to investigate the role and contribution of MBL to the risk 
of bacterial infections in early life (preterm neonates) and in Human Immunodeficiency 
Virus (HIV) in children.
The specific aims of this study are:
1) To explore the influence of MBL gene polymorphisms on the susceptibility and 
severity of infection in preterm neonates
2) To evaluate the developmental profile in MBL levels during the month of life as a 
function of gestational age and birth weight
3) To investigate a role of MBL in the susceptibility and progression of HIV disease.
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CHAPTER 2
METHODOLOGY
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2.1 MBL GENOTYPING
2.1.1 DNA extraction
Genomic DNA was extracted from 200 p,l whole blood using a commercial kit (QIAamp 
DNA blood Mini Kit, Qiagen, Crawley, UK) according to the manufactures instructions. 
The QIAamp DNA purification procedure comprises three steps and is carried out using 
QIAamp spin columns in a standard microcentrifuge (M-24 BOECO, Germany). Briefly, 
200 pi whole blood was mixed with 20 pi of Qiagen Protease in a 1.5 ml 
microcentrifuge tube. 200 pi Buffer AL was added to the sample and mixed by pulse- 
vortexing for 15 s and heated at 56 ° C in a water-bath (Grant Instruments, Cambridge, 
UK) for 10 minutes. 200 pi of absolute ethanol (Sigma-Aldrich, Poole, UK) was added 
and the resulting solution was vortexed and centrifuged (6 500 rpm, I min). The 
supernatant obtained after centrifugation was applied to a sterile spin column (held in a 
collection tube) and re-centrifuged (6500 rpm, 1 min). Specific binding of genomic 
DNA to the spin column allowed contaminants to be discarded in the collection tube. 
The spin columns were placed in clean 2 ml collection tubes (provided in kit). 500 pi of 
Wash buffer AWl was added to the column and re-centrifiiged (6 500 rpm, I min) 
followed by a second wash with 500 pi of wash buffer AW2 and re-centrifuged (13 000 
rpm; 3 min.). The spin columns were removed and placed in clean 1.5 ml tubes before 
elution of genomic DNA from the column by the addition of 200 pi of sterile water. 
Extracted DNA (approx. 10 ng/pl) was stored at -20 °C until further use.
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2.1.2 MBL genotyping by heteroduplex generation
Detection of mutations by molecular techniques allows one to correlate genotype with 
phenotypic changes in an organism leading to a better understanding of mode of disease 
inheritance. In mutation detection, test DNA molecules are compared for differences 
from reference wild-type DNA. In this study, PCR of specific regions followed by 
hetero-duplexing was used to identify specific MBL mutations. Previous methods for 
genotyping have included restriction enzyme analysis of polymerase chain reaction 
(PCR) products (Lipscombe et al, 1992; Madsen et al, 1994), probing with 
radiolabelled allele specific oligonucleotides (Madsen et al, 1994), and the 
amplification refractory mutation system (Davies et a l, 1995).
Intra-strand base pairing causes single-stranded DNA molecules to form complex 
secondary structures. Alteration of the nucleotide sequence of the molecule by as little as 
a single base can reshape the secondary structure, with consequent changes in 
electrophoretic mobility. Hetroduplexing exploits the differences in mobility between 
wild-type and mutant strands of DNA. The sequence of interest is amplified by PCR 
from genomic DNA. The PCR DNA product is denatured and then analyzed by agarose 
gel electrophoresis under non-denaturating conditions at neutral pH. A wild-type 
molecule generates two bands corresponding to each single strand of the PCR product.
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2.1.2.3 Heteroduplex generators
Cross-matching an unknown DNA with a specially constructed third party DNA, termed 
a universal heteroduplexes generator (UHG) was adapted from Wood et al., (1993). 
These are syntetic DNA sequences that mimic a genomic DNA sequence, but which 
contain nucleotide substitutions, deletions or insertions at nucleotide positions opposite 
to and contiguous (upstream and downstream) with known mutation sites within 
genomic DNA. The UHG and genomic DNA sequences are amplified with the same 
PCR primes, and are hybridised together in equal proportion post-PCR by heating and 
slow cooling. This generates DNA heteroduplexes having different conformational 
forms, and thus different electrophoretic mobilities, characteristic for individual alleles 
of a gene (Wood et al, 1993).
In the present study MBL exon-1 genotyping was done by specific amplification of 
exon-1 by polymerase chain reaction (PCR). In a separate reaction a synthetic DNA 
(UHG) based on exon-1 was also amplified using the same primer set. The two reaction 
products were combined, denatured and annealed to form homo and heteroduplexes 
before being subjected to polyacrylamide gel electrophoresis. The data from 
heteroduplexing procedures were combined to give haplotypes comprising one of the 
three structural mutations (O) or wild-type (A) together with the X/Y promoter 
polymorphism.
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2.1.3 PCR amplification of genomic DNA and UHG
The exon-1 mutation spanning and the X/Y promoter region were amplified by PCR 
using genomic DNA as template. The conditions for the PCR reactions have previously 
been optimized (Jack et al., 1997; Turner et al, 2000). Also, similar PCR reactions 
were performed for the UHG. Routinely, the PCR reaction was performed in 20 pi total 
volume using; 5 pi of aqueous DNA (approximately 10 ng/ pi), 0.6 pi each of 50 pM 
MBL primers (Genosys Biotechnologies Ltd., Pampisford, Cambs, UK):
Sense- MBL - (5 - CCAACACGTACCTGGTTCC-3 ),
Antisense -MBL - (5 - CTGTGACCTGTGAGGATGC-3 ),
2 pi of 10 X PCR buffer, 2 pi of dNTPs mix (2 mM each of dATP, dCTP, dGTP and 
dTTP) (Invitrogen, Paisley, Scotland), 1.2 pi of 25 mM MgCL, 0.2 pi of AmpliTaq 
Gold DNA polymerase (Roche Molecular Systems, Branchburg, New Jersey, USA) and 
sterile water (Sigma, UK).
The PCR reactions for the promoter polymorphisms were conducted under similar 
conditions using the following primers (Genosys Biotechnologies Ltd., Pampisford, 
Cambs, UK):
Sense MBL promoter - (5 - AGGCATAAGCCAGCTGGCAAT-3 '),
Antisense MBL promoter - (5'- CTAAGGAGGGGTTCATCTG-3')
PCR reactions were carried out in a thermacycler (Phoenix, Helena BioSciences, 
Sunderland, UK) and the conditions were 95 ° C for 15 minutes, followed by 35 cycles 
of 95 ° C for 45 seconds, 56 ° C for 45 seconds and 12° C for 45 seconds. These were 
followed by a final extension step at 72 ° C for 10 minutes.
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2.1.3.1 PCR amplification o f UHG
Using the commercial UHG as the template, supplied by MWG-Biotech AG (Ebersberg, 
Germany) large scale PCR reactions were initially performed to obtain quantities of 
stock UHG generator that could be utilized in a series of subsequent reactions. Reagents 
used for large scale prep were: ~ 5 pg of the appropriate UHG template,
18 pi of 50 pM MBL primers:
Sense MBL - (S'- CCAACACGTACCTGGTTCC-3'),
Antisense MBL - (S'- CTGTGACCTGTGAGGATGC-3 )
A separate reaction for the promoter UHG region was performed:
18 pi of SO pM MBL primers:
Sense MBL promoter - (S'- AGGCATAAGCCAGCTGGCAAT-3 '),
Antisense MBL promoter - (S '- CTAAGGAGGGGTTCATCTG- 3 )
100 pi of 10 X PCR buffer, 100 pi of dNTPs mix, 60 pi of 25 mMgClz, 2.6 pi of 
AmpliTaq Gold DNA polymerase, and 78S pi sterile water.
PCR reactions were carried out at 9S ° C for IS minutes, followed by 3S cycles of 9S ° C 
for 45 seconds, S6 ° C for 45 seconds and 72° C for 45 seconds. These were followed by 
a final extension step at 72 ° C for 10 minutes.
2.1.4 Analysis of PCR products by agarose gel electrophoresis
All PCR products were routinely tested for integrity on 2 % agarose gels prior to 
heteroduplexing and genotyping. Agarose gels were prepared as follows: 2 g Agarose 
(Sigma- Aldrich) was dissolved in 100 ml Tris- Borate- EDTA Buffer (TBE), (stock 
solution, 10 X concentrate. Sigma- Aldrich) by microwave heating. Agarose was cooled
42
before addition of 10 |ig ethidium bromide (stock solution=5 mg/ml, Sigma, Poole, UK) 
and set in appropriate casting tray. 1 pi of 6 X Loading Buffer (Promega, Southampton, 
UK) was added to 3 pi of PCR product. A 1 kilobase Ladder was included as a marker 
(Promega, Southampton, UK). The gels were run in TBE buffer at 100 V for 1 hour. 
PCR products were visualised using the Alphalmager system (Alpha Innotech, San 
Leandro, CA, USA).
2.1.5 MBL heteroduplexing by polyacrylamide gel electrophoresis
Following confirmation of specific amplification of genomic and UHG DNA, 10 pi of 
UHG PCR product plus 5 pi of loading dye were added to 15 pi of each DNA sample. 
The combined samples were heated to 95 ° C for 10 minutes and then allowed to cool to 
room temperature over 20 minutes to allow slow and specific annealing. 15 pi of the 
heteroduplex product was loaded onto a 20 % polyacrylamide gel for genotyping. The 
gel was prepared as follows:
20 ml 30 % Acrylamide/ Bis Acrylamide, stock solution (Severn Biotech LTD, UK), 6 
ml of 10 X TBE Buffer (Sigma, Poole, UK), 300 pi 10 % ammonium persulfate solution 
(National Diagnostic, UK), 30 pi TEMED (N, N, N, N, -tetramethylethylenediamine), 
(Sigma, Poole, UK) and 5 ml MiliQ water. The gel was allowed to set (acrylamide 
polymerisation for 5-10 min. at room temperature). After polymerization was complete, 
the gels were attached to the electrophoresis tank, using clips. The notched plate faced 
inward toward the buffer reservoir. Heteroduplex samples were loaded and run for 16 
hours at 140 V in TBE buffer at room temperature. Gels were stained using 0.5 pg/ ml
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ethidium bromide in TBE buffer for 10 minutes before photography under UV light 
(Alpha Imager system, Alpha Innotech, San Leandro, USA).
As well as faster homoduplex formation, this technique also allows heteroduplex 
formation between two different DNA molecules. Due to the known mutations in the 
promoter and exon-1 region of the MBL gene one may expect two different 
heteroduplexes per allele with differing electrophoretic mobilities. Each allele should 
generate two different DNA heteroduplexes corresponding to the two DNA strands from 
each allele. Homozygotes generated two heteroduplex bands and heterozygotes 
generated four heteroduplex bands which were visualized and quantified. A 
representative polyacrylamide gel showing heteroduplexing pattern for X/Y  promoter 
polymorphism obtained in the present study is shown below (Figure 2.1).
Figure 2.1 Polyacrylamide gel showing promoter polymorphism Y/Y, X/ Y, X7 X 
(performed by Researcher A.D.)
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Figure 2.2 Diagram presenting summarized methods of MBL genotyping
45
2.2 MBL PHENOTYPE
MBL protein levels in serum were determined by a symmetrical sandwich enzyme- 
linked immunosorbent assay (ELISA) using commercial MBL Oligomer ELISA Kit 
(Antibody Shop, Copenhagen, Denmark) using instructions recommended by the 
manufactures. Briefly, the assay was performed in 96 microwells coated with a 
monoclonal antibody against the MBL carbohydrate-binding domain. Bound MBL is 
detected with the same antibody labelled with biotin, followed by colour development 
after incubation with horseradish peroxidase (HRP)-con) ugated streptavidin and a 
chromogenic substrate.
The assay is four step procedures which are:
Step 1: MBL standards (0, 0.5, 1, 2, 5, 10, 20, 40 ng/ml), diluted patient sera and 
controls were incubated in duplicates in microwells pre-coated with monoclonal 
antibody against MBL for 60 minutes at room temperature (RT) on a shaking platform 
(R 100/ TW Rotatest Shaker, Denley Instruments, Billinghurst, UK) set at 200 Revs/ 
minute. Unbound material was removed by washing using wash solution provided with 
kit and washer plate (Microtitration Plate Washer, ADIL Instruments, France). The 
microwells were washed three times.
Step 2: 100 pi of biotinylated monoclonal detection antibody was added to each 
microwell and incubated for 60 minutes at RT on a shaking platform. Unbound antibody 
was removed by washing using wash solution (as described in step 1).
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Step3: 100 \i\ of HRP-conjugated streptavidin was added to each test well and incubated 
for 60 minutes at RT on a shaking platform (200/ minute). This step allowed complex 
formation with the bound biotinylated antibody. Unbound conjugate was removed by 
washing using wash solution (as described above)
Step 4: 100 pi of chromogenic peroxidase substrate containing tetramethylbenzidine 
(TMB) was added to each well and incubated for exactly 15 minutes at RT in the dark. 
The bound HRP- streptavidin reacts with the substrate to generate a colored product. 
The enzymatic reaction was stopped chemically by adding lOOpl Stop solution 
(provided). The color intensity was read at 450 nm in an ELISA reader (MRX, Dynatex 
Laboratories,) within 30 minutes. The optical density readings obtained for the standard 
MBL were utilised to construct a calibration curve from which the concentrations of 
MBL in the test specimens were calculated.
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2.3 STATISTICAL ANALYSES
Data were analyzed using SPSS version 12.0 (SPSS, Inc, Chicago, IL, USA). Patients 
were classified according to their MBL exon 1 mutations as wild-type (A/A), 
heterozygous (A/0), or homozygous (0/0). Genotype (or allele) frequencies were 
analysed by the Chi-square test. Graphs and summary measures were used to look at 
distribution of data. The methods used in descriptive statistics include histograms and 
normal plots. As analyzed data were found non-normally distributed, summary were 
presented as median and interquartile range (IQR). Non-parametric tests: Mann-Whitney 
and Kruskal-Wallis were used in analysis. Differences between groups (MBL serum 
levels) were compared with the Mann-Whitney U Test (for two groups) or Kruskal- 
Wallis test (three or more groups). Relations between different variables were tested 
using the Spearman rank correlation test. Probability values were two-sided, and 
significance was defined as p < 0.05. MBL levels are presented in the text and 
graphically as median values. Graphs demonstrate median (bar), interquartile range 
(IQR); (box) and range (whiskers). Data points that lay more than 1.5 IQRs outside the 
IQR were marked individually as outliners. Statistical analyses presented in Chapter 4 
were performed with SPSS version 12.0 (SPSS, Inc, Chicago, IL, USA) and with SAS 
version 9.1 (SAS®, Cary, NC, USA). The analyses of the risk of sepsis according to 
MBL levels, birth weight and gestational age at birth were performed using logistic 
regression.
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CHAPTERS
MBL IN HIV INFECTION IN CHILDREN: 
RELATION TO DISEASE PROGRESSION AND 
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
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3.1 INTRODUCTION
Human immunodeficiency virus (HIV) infection still represents one of the most 
important health problems in the world. The spread of HIV infection in developed 
countries is a consequence of sexual lifestyle, intravenous drug use, and treatment with 
contaminated blood products. According to the World Health Organization (‘WHO’) 
estimates and the Joint United Nations Programme on HIV/ AIDS (‘UNAIDS’) report 
2007 AIDS Epidemic Update:
• In 2007, some 33.2 million individuals were living with HIV worldwide, 
compared with 39.4 million in 2004;
• 2.5 million individuals had become newly infected and 2.1 million individuals 
had died of AIDS (compared with 3.1 million in 2004);
• 2.5 million children were estimated to be living with HIV in 2007 (unchanged 
from 2004), 90 % of them in Africa.
These data reflect advances in methodology that have resulted in substantial revisions 
from previous estimates The epidemic estimates presented in the report reflect 
improvements in country data collection and analysis, as well as a better understanding 
of the natural history and distribution of HIV infection. In the past few years a number 
of countries, most notably in sub-Saharan Africa and Asia, have expanded and improved 
their HIV surveillance systems, conducting new, more accurate studies that provide 
more precise information about HIV prevalence than earlier studies. In addition, 30 
countries mostly in Africa have conducted national representative population-based 
household surveys. These have also informed adjustments for other countries with
50
similar epidemics that have not conducted these surveys. New assumptions have also 
been made as a result of a better understanding of the natural history of untreated HIV 
infection.
The single biggest reason for the reduction in global HIV prevalence figures in the past 
year was the recent revision of estimates in India after an intensive reassessment of the 
epidemic in that country. The revised estimates for India combined with important 
revisions of estimates in five sub-Saharan African countries (Angola, Kenya, 
Mozambique, Nigeria, and Zimbabwe) account for 70% of the reduction in HIV 
prevalence as compared to 2006 estimates.
In recent years Highly Active Antiretroviral Therapy (HAART) has dramatically 
improved clinical, virologie and immunological parameters in HIV-infected individuals, 
although a favourable response is not achieved in all patients (Tozser, 2001). 
Importantly, HAART does not eradicate the virus, and for several immunologic 
parameters, there is no normalization during therapy (Blankson, 2002). Thus, additional 
treatment modalities are needed and immunomodulatory therapy in combination with 
HAART may represent such an option. Several studies have begun to explore a potential 
immunological role for MBL in HIV infection. These studies are discussed in more 
detail below.
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3.1.1 Direct MBL and HIV-1 viral interactions
The role of MBL in HIV disease has been extensively studied both in vitro and vivo, but 
has resulted in somewhat conflicting findings. It was first demonstrated in vitro that HIV 
infection of CD4 + T lymphocytes was impaired by physiological concentrations of 
MBL (Ezekowitz et al, 1989). In 1989, Ezekowitz and colleagues observed binding of 
purified MBL to HIV infected cell lines and MBL inhibited HIV infection of 
lymphoblasts (Ezekowitz et al, 1989).
Several studies have investigated the molecular interactions between MBL and HIV. 
HIV virus envelope proteins, such as HIV gpl20 and gp41, contain carbohydrates that 
enable binding to MBL. HIV gp 120 is highly glycosylated with about half of the 
120kDa molecular weight consisting of N-linked glycans. In contrast, there are only four 
or five potential N-linked carbohydrate sites on gp41. MBL is now known to recognize 
gp 120 in a sugar specific manner via its’ CRD since the interaction could be inhibited by 
EDTA, mannan or N-glycanase treatment (Ezekowitz et al, 1989; Saifuddin et al, 
2000; Thielens et al, 2002; Hart et al, 2003).
MBL binds to both CCR5-tropic and CXCR4 tropic primary isolates (PI) of whole virus 
(Saifuddin et al, 2000). Binding of virus to MBL required expression of gpl20/gp41 on 
virus particles, suggesting the presence of either a usually high carbohydrate density 
and/or a unique carbohydrate structure on gpl20/gp41 that is a target of MBL. The study 
by Saifuddin and co-workers suggested that MBL can selectively interact with HIV via
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the high-mannose glycosylation sites of gpl20/gp41 which play a major role in MBL- 
HIV interactions (Saifuddin et al, 2000).
These results indicated that MBL recognizes high-mannose glycans know to be present 
on gp 120 in the domain that is recognized by CD4 cells and thereby inhibits viral entry 
to susceptible cells. In vitro, binding of gpl20 to the cell-surface marker, CD4, on the 
surface of the T cells is inhibited by MBL. This neutralizing effect is related to 
complement, but is independent of Clq, or antibodies or viral lysis (Haurum et al, 
1993). Association of MBL with the viral surface may lead to activation of the lectin 
pathway and viral lysis (Haurum et al, 1993).
The recent study, by Ying and co-workers has reported the MBL binds to both PI and 
cell line-adapted HIV but does not effect neutralization by levels of MBL normally 
present in serum. However, binding and opsonization of HIV by MBL may alter virus 
trafficking and viral-antigen presentation during HIV infection (Ying et al, 2004). MBL 
may influence uptake by DCs which express a cell surface lectin called “dendritic cell- 
specific intracellular adhesion molecule 3 (ICAM-3)-grabbing non-integrin” (DC- 
SIGN). DC-SIGN has been shown to mediate a type of infection called “trans” infection, 
when DCs bind HIV and efficiently transfer the virus to T cells (Geijtenbeek et al, 
2000; Geijtenbeek and van Kooyk, 2003). A recent study showed that preincubation of 
HIV strains with MBL, at levels similar to those found in normal human serum, could 
inhibit the HIV infection of T cells mediated by DC-SIGN (Spear et al, 2003).
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3.1.2 MBL and susceptibility to HTV infection in adults
It has been suggested that MBL deficiency, as assessed by MBL serum concentrations, 
increases susceptibility to HIV infection in adults (Nielsen et al, 1995; Garred et al, 
1997; Prohaszka et al, 1997). Nielsen et al, studied a population of 80 HIV infected 
patients and 123 normal healthy individuals. The number of HIV positive individuals 
with undetectable MBL levels was significantly higher than in healthy controls (Nielsen 
et al, 1995). Two studies conducted by Garred and co-workers in European and African 
population respectively reported that MBL deficiency, as assessed by genetic methods, 
was more frequent in HIV infected individuals when compared to healthy controls 
(Garred et al., 1997a, b). HIV infected patients were more likely to be homozygous for 
MBL variant alleles (Garred et al., 1997a). Another study performed by Pastinen et al 
1998 in a Finish population suggested also that homozygosity for the MBL variant 
alleles occurred more frequently in HTV infected patients (Pastinen et al, 1998). A 
recent study performed by Vallinoto and co-workers in a Brazilian population has 
provided further evidence that homozygosity for the MBL variant alleles is associated 
with HIV-1 transmission (Vallinoto et al, 2006). Several other studies, however, did not 
find similar associations (Senaldi et al, 1995; Maas et al, 1998; Malik et al, 2003). For 
example, Senaldi et al, 1995 found that MBL levels were higher in HIV infected 
individuals than normal controls. In another study by Malik et al, 2003, MBL genotype 
frequencies were similar in HIV-infected and control individuals in a Colombian 
population. Table 3.1 shows published adults studies related to HIV disease (Tables 3.1).
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3.1.3 MBL and HTV disease progression in adults
The effect of MBL on HIV disease progression has also been investigated (Senaldi et 
al, 1995; Nielsen et al, 1995; McBride et al, 1998). A number of studies have failed to 
show any effect of MBL status on disease progression (Senaldi et al, 1995; Nielsen et 
al, 1995; McBride et al, 1998). However, a few studies actually reported a weak 
protective effect of MBL-2 mutant alleles on progression to AIDS and death (Maas et 
al, 1998; Prohaszka et al, 1998). Mass and co-workers showed that HIV infected 
patients with the mhl variant alleles progressed more slowly to AIDS (Maas et al, 
1998). Prohaszka reported that MBL levels negatively correlated with CD4+ T 
lymphocytes (percentage and absolute number) suggesting that MBL deficiency could 
be beneficial (Prohaszka et al, 1998). Interestingly, Garred and colleagues found that 
individuals with one or more MBL variant alleles had a shorter survival time after a 
diagnosis of AIDS in an adult Danish homosexual population (Garred et al, 1997a). A 
recent study by Vallinoto and co-workers has also showed that normal MBL serum 
concentrations were required for control of viraemia and therefore may act to limit a 
disease progression (Vallinoto et al, 2006).
A few studies have attempted to examine MBL status in HIV-infected patients in the 
context of Antiretroviral Therapy (ART) (Hundt, et al, 2000; Heggelund et. al, 2003). 
In a study by Hundt et al, 2000, normal MBL levels were found in six long term 
nonprogressors (LTNPs). They concluded that possession of wild type MBL genotype is 
protective against HIV infection (Hundt, et al, 2000). Only one study to date has been 
performed in the era of treatment with HAART (Heggelund et. al, 2003). The authors
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observed an increase in MBL levels in advanced HIV disease suggesting that MBL may 
modulate HIV disease progression. Table 3.1 shows published adults studies related to 
HIV disease (Table 3.1).
3.1.4 MBL and HIV infection in paediatric studies
A clear difference in natural HIV progression between adults and children has been 
observed with respect to transmission, pathogenesis and clinical manifestations (Scott et 
al, 1984). Studies investigating the role of MBL in paediatric HIV infection are limited. 
Amaroso and colleagues showed that the codon 54 polymorphism in the MBL-2 gene 
was associated with AIDS progression (Amoroso et al, 1999). Another study by 
Boniotto and co-workers found MBL-2 promoter polymorphisms influenced both the 
risk of infection as well as disease progression (Boniotto et al, 2000).
An association between the presence of any one of the three exon-1 MBL-2 alleles and 
HIV infection in perinatally exposed Brazilian children has also been reported (Boniotto 
et al, 2003). A study by Lian et al, 2004 showed that MBL concentrations were 
increased in more severe clinical stages of the HIV disease (Lian et al., 2004). Table 3.2 
shows published paediatric studies related to HIV disease (Table 3.2).
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Study Patient
population
(n)
Assay Findings
Susceptibility Severity
Senaldi 
etal, 1995
92
Europe
ELISA MBL levels higher in HIV infected 
patients
No difference in MBL levels between CDC groups. 
No correlation with CD4+T cells.
Nielsen 
etal, 1995
80
Denmark
ELISA Undetectable MBL levels in HTV 
infected patients
No association
Garred 
etal, 1997 a)
173
Africa
ELISA Low MBL levels associated with 
increased risk of HIV infection
Not done
Garred
etal, 1997 b)
96
Denmark
Genotype
ELISA
Higher rate of homozygous carriers 
of mbl variant alleles
Homozygous- mbl variant alleles had shorter 
survival time after AIDS diagnosis
Prohaszka 
etal, 1997
67
Europe
ELISA Low MBL levels in HIV infected 
patients
Negative correlation between 
MBL levels and CD4+ T cells
Maas
etal, 1998
131
Netherlands
Genotype Not done Homozygous- mbl variant alleles progressed 
more slowly to AIDS
McBride 
etal, 1998
131
UK
Genotype
ELISA
No association No association
Pastinen 
etal, 1998
300
Finland
Genotype Increased rate of homozygous - mbl 
variant alleles in HTV (+) ve
Not done
Malik 
et al, 2003
278
Colombia
Genotype No association Not done
Heggelund 
et al, 2003
62
Norway
ELISA Not done MBL levels markedly elevated in CDC group C
Vallinoto 
et al, 2006
145
Brazil
Genotype Association of variant B with HTV 
infection
Lower CD4+ T cells & higher viral load in carriers 
of mbl B allele.
Table 3.1 Studies investigating MBL and HIV infection in adults
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Table 3.2 Summary of studies relating MBL status and HIV infection in children
Study Patient population
(n)
Assay Findings
Susceptibility Severity
Amaroso 
etal, 1999
52 HIV (+) ve & 27 
exposed HIV(-) ve 
Italy
Genotype 
codon 54
Higher frequency of 
variant alleles in HTV 
infected patients
Presence of variant alleles 
associated with rapid 
progression
Boniotto 
et al, 2000
n=90;
vertically acquired 
HTV infection 
Italy
Genotype
Promoter-
Position
-550
Promoter 
polymorphism 
associated with vertical 
transmission of HTV
Homozygous-variant 
alleles associated with 
rapid progression to 
AIDS
Boniotto 
et al, 2003
n=114 perinatally 
HTV infected & 27 
exposed HIV(-) ve 
Brazil
Genotype - 
exonl
Variant mbl gene 
alleles more frequent in 
HTV infected patients
Not done
Lian et al, 
2004
n=127
Brazil
ELISA Not done Trend for higher MBL 
levels in more severe 
patients (CDC stage C)
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3.1.5 Long-Term Non-Progressors (LTNP) in HIV infection
Initial studies of HIV-infected persons focused mainly on individuals presenting with 
symptoms of AIDS, who therefore represent the most severely affected end of the 
spectrum disease. From adults’ studies, over time it has been possible to identify 
individuals who are infected with HIV and yet whose immune system remains 
undamaged > 20 years following infection. In these Long-Term non-Progressors 
(LTNP), HIV replication is suppressed to very low levels due to effective immune 
responses (Cytotoxic T lymphocytes, T-helper cells or neutralising antibody responses) 
and/or the host genetic factors that play an important role in susceptibility to HIV-1 
infection and in the rate of disease progression i.e. CCR5 and CXCR4 genes (HIV-1 co­
receptors); (Alvarez et al, 1998). A balance between the host factors and virus factors 
are major determinants of the outcome of HIV infection.
Paroli and co-workers defined LTNP HIV-infected individuals characterized by the 
absence of disease with low viral loads and stable or even increasing CD4 (+) T cell 
counts for prolonged periods of time. In these subjects, an HIV-specific immune 
response which is either stronger or directed against a wider array of viral epitopes than 
that seen in progressors, can be observed (Paroli et a l, 2001).
According to definition by Suzuki and Yamamoto, 1997 the length of time between HIV 
infection and development of AIDS was considered to be 10 years on average, but a few 
percent of infected persons-so-called LTNP, did not develop AIDS even more than 10 
years after infection. In LTNP it has been described that 1) there is a low viral load, 2)
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isolated HIV is relatively non virulent type, 3) antibody to HIV do not enhance virus 
propagation, 4) type 1 cytokines is more dominant than type 2, and 5) antiviral activity 
of CD8+ T cells is strong. In LTNP the immune-responses actively suppress HIV 
proliferation, so that viruses are controlled at low level (Suzuki and Yamamoto, 1997).
Rodes and co-workers described the main features of LTNP and presented longitudinal 
virology and immunology follow-up for a 6-years period. Cohort of 19 patients with 
evidence of non- progressive HIV-1 infection was established in 1997 in reference 
HIV/AIDS center in Madrid. All patients had serologically proven HIV-1 infection for at 
least 10 years, repeated CD4 cell counts > 500 x 10^  cells/1, and no prior history of HIV- 
related symptoms, in the absence of any antiretroviral therapy. All of these individuals 
have been prospectively followed every 4-6 months since January 1997 (Rodes et al, 
2004).
HIV-1-positive LTNP who were enrolled in the Australian LTNP study, had been 
infected with HIV-1 for at least 8 years and maintained a CD4+ T cell count of > 500 x 
10^ /1 in the absence of anti-retroviral therapy. HIV-1 progressors were selected from the 
Sydney AIDS prospective study and consisted of individuals who were infected at 
around the same time and known to have progressed to AIDS and/or death within 8 
years of HIV-1 infection (Clegg et al, 2000).
Paediatric studies on LTNP are more complicated. Earlier studies have shown the speed 
of progression to disease in paediatric HIV infection is related to extent of progression in 
the mother at the time of birth (Blanche et a l, 1997). More than 90 % of HIV-1
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infection in children was acquired by mother-to-child-transmission (Scarlatti, 1996). 
Approximately 20 % of HIV-1 infected children bom to seropositive mothers’ 
progressed rapidly during the first year of life towards development of AIDS 
(progression to U.S. Centers for Disease Control and Prevention (CDC) group C disease 
or HIV- related death), and 4.7% per year thereafter, giving a cumulative incidence of 
36% by 6 years (Blanche et al, 1997).
Studies in North America and Europe, prior to implementation of antiretroviral therapy 
(ART), identified a group -25% of children infected around the time of birth who 
progress very rapidly to AIDS within one year of life (European Collaborative Study); 
(Sharland et ah, 1997). Of the remaining 75%, the median survival time was 7 years 
(Barnhart et al, 1996). In sub-Saharan Afi-ica, the figures indicated that at least 89% of 
children infected with HIV perinatally died with AIDS by the age of 3 years (Taha et al, 
2000). Observation of cohorts of perinatally infected children showed that there are 
children who have survived well beyond the median life expectancy of 8 years for those 
in developed countries (pre-therapy) who have had not developed AIDS in the first year 
of life. However most of these children have high levels of virus and it was not possible 
to study mechanisms which control viremia.
According to Vigano and co-workers, 1997 some children who are infected with HIV-1 
during the perinatal period remain asymptomatic for very long periods in the absence of 
antiretroviral treatment, as is the case for some adults. Vertically infected children 
showing resistance to disease progression are immunologically and virologically distinct 
fi"om those in whom progressive HIV infection is observed. LTNP were defined in 
vertically infected children > or = 8 years of age without disease progression or mild
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symptoms and an absolute CD4+ T cells count > or = 500/microliter with CD4+ 
percentage > or = 25% (Vigano et al, 1997). LTNPs maintain a very low viral load in 
plasma, virus is less cytopathic and they have predominant T-helper cell profile and their 
cellular CDS T cell antiviral response is strong (Romiti et al, 2000).
The recently published study by Warszawski et al, 2007 reported the proportion of 
children who developed neither symptoms nor major immunological perturbations to the 
age of 5^ 10 years in a prospective French Pediatric Cohort of 568 HIV-1 infected 
children who had been observed since birth. Children with long-term non-progression of 
infection (LTNPs) were defined as HIV-1 infected children who had been observed for 
at least 10 years, never received antiretroviral treatment other than zidovudine 
monotherapy, never developed symptoms of Centers for Disease Control and Prevention 
clinical category C or B, and had a CD4^ cell percentage of <25% no more than once 
during follow-up (Warszawski et al 2007).
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3.2 AIMS
The aims of the study described in this chapter were:
1) To access the MBL genotype distribution in the UK cohort of HIV-infected children
2) To explore the potential correlation between the course/ severity of HIV infection and 
MBL genotype and phenotype
3) To investigate the role of MBL in the progression of HIV disease in HIV Long Term 
non-Progressors (LTNPs).
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3.3 PATIENTS and METHODS
3.3.1 Patients
One-hundred and twenty-eight HIV infected children (64 females) attending the HIV 
Family Clinic at Great Ormond Street Hospital for Children NHS Trust, (GOSH) 
London, UK between January 2003 and August 2004 were recruited. Approval for the 
study was granted by the Great Ormond Street Hospital for Children/ Institute of Child 
Health Research Ethics Committee and parental written consents were also obtained. At 
the time of blood sampling, the patients’ clinical notes were assessed and all children 
included were classified according to the Centres for Disease Control and Prevention 
(CDC; Atlanta, GA, USA) revised classification (clinical and immunological) system 
detailed in Tables 3.3 and 3.4 for HIV infection in children (CDC, Revised 
Classification, MMIFX 1994).
Children who had not taken ART were defined as antiretroviral therapy naive (ARTN). 
To identify HIV infected children in our studied cohort at GOSH who are LTNP the 
definition of paediatric LTNP was adopted from ongoing parallel LTNP study 
coordinated by Professor Philip Goulder fi*om John Radcliffe Hospital, Oxford. This was 
multi-centre, including patients from GOSH, longitudinal study of LTNP investigating 
protective HIV specific immune responses. The aim of the multi-centre LTNP study was 
to identify and study perinatally infected children who represent the best <5% in terms 
of non-progression to disease, relative preservation of the immune system despite HIV 
infection, and successful control of viremia.
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Children who are antiretroviral therapy naive (ARTN) were defined for the purpose of 
this study as LTNP who fulfill the following criteria:
• >24 months of age and
• Viral load<10,000 copies of HIV-1 RNA/ml at enrollment on the LTNP study 
and
• CD4% > 20% at enrollment on the LTNP study.
Table 3.3 Classification of HIV infected children according to clinical symptoms
(1994 Revised, MMWR)
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Table 3.4 Classification of HIV infected children according to immunological 
impairment (1994 Revised, MMWR)
3.3.2 Samples collection
Whole blood was collected in lithium heparin tubes for serum isolation. The isolation 
procedure involved centrifugation of whole blood (M-24 BOECO, Germany; 2 000 rpm, 
7 min). The supernatants were aliquoted into fresh tubes and stored at - 80 ° C. Whole 
blood was also collected in an EDTA tubes and stored at -80 ° C until required for DNA 
extraction. DNA was isolated and frozen at -20 ° C until required for MBL genotyping. 
The immunological and virological markers of disease progression (CD4+T cells, 
CD8+T cells, CD3+T cells, HIV-1 RNA viral load) and MBL measurements (genotype 
and phenotype) were performed for each patient.
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3.3.3 Methods
The methods used for assessing MBL genotype and phenotype and statistical analyses 
are described in detail in Chapter 2. Chi-square or Fisher’s exact test was used to 
compare proportions in two groups (MBL genotype in HIV studied group and published 
control groups). The analysis was performed using Stata version 10 statistical 
programme (StataCorp, USA).
3.4 RESULTS
3.4.1 Patient characteristics
One-hundred and twenty-eight HIV infected children (64 females) were enrolled. MBL 
genotyping was performed in all 128 children and serum MBL levels were measured in 
127. The median age at enrolment was 8.9 years (range 1.4-16.1 years). Seventy=nine 
percent jjLghildren were of Sub-Saharan origin, 7 % were white, 9 % were of mixed 
origin (white and African, or white and unknown) and 5 % for whom place of birth or 
either biological parent were unknown. Table 3.5 shows patients’ characteristics 
according to the CDC clinical and immunological classification (Table 3.5).
Eighty-three individuals were receiving or had received HAART. Of the 45 individuals 
who were classified as ART naive (ARTN), 10 were LTNPs. The relation between 
patients ART status and CDC classification is shown in Table 3.6. Children who were 
not classified as ARTN or LTNPs had taken HAART, and therefore described as the 
HAART group.
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Table 3.5 Classification of HIV-1 infected children based on clinical and 
immunological parameters.
Clinical category, n (%) Immunological category, n (%)
A B C 1 2 3
Male 19(48.7) 30 (51.7) 15 (48.4) 38 (49.3) 22(47.8) 4 (80.0)
Female 20 (51.3) 28 (48.3) 16(51.6) 39 (50.7) 24 (52.2) 1 (20.0)
Total 39 58 31 77 46 5
Table 3.6 Classification of HIV-1 infected children based on therapy, clinical and 
immunological parameters.
Clinical category, n (%) Immunological category, n (%)
A B C 1 2 3
LTNPs 5 (12.8) 5 (8.6) 0 7 (9.1) 3 (6.5) 0
ARTN 19(48.7) 16 (27.6) 0 19 (24.7) 15 (32.6) 1 (20.0)
HAART 15(38.5) 37(63.8) 31 (100) 51 (66.2) 28 (60.9) 4 (80.0)
Total 39 58 31 77 46 5
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3.4.2 HTV and MBL genotype
All 128 individuals were genotyped for MBL-2 mutations. Table 3.7 shows the genotype 
frequencies of structural gene variants in the MBL-2 in this patient cohort. 77.3 % of the 
patients were homozygous for wild type MBL alleles. The 22.7% of the patients were 
heterozygous (18%) and 4.7 % homozygous for variant MBL alleles. The C allele was 
predominant. It was found in 76 % of heterozygous (A/0) individuals compared to 
patients with the B (9.6%) and D (14.4 %) alleles (Table 3.7). To explore the difference 
in gene distribution between different ethnic groups, the genotype analysis was 
performed for the whole study population and separately for Black Afncan population 
(the majority of the children in the study, n=101).
Table 3.7 MBL exon-1 genotype frequencies in HIV-1 infected patients
MBL
exon-1 genotype
studied group 
Total
n= 128 (%)
Studied 
African 
n=101 (%)
A/A 99 (773) 74 (73.3)
A/B 2 (1 .6 ) 2 (2.0)
A/C 17(13.3) 16(15.8)
A/D 4 (3.1) 3(3.0)
A/O 23 (18.0) 21 (20.8)
B/B 0 0
C/C 4(3.1) 4 (4.0)
D/D 0 0
B/C 0 0
C/D 2(1.6) 2 (2.0)
0 / 0 6(4.7) 6 (6.0)
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Additionally, we analysed the genotype frequencies including the promoter 
polymorphism at position -221 in the MBL-2 gene in this patient cohort (Table 3.8). The 
-221 promoter polymorphism (X/Y) was chosen as it greatly influences protein level 
(Madsen et al, 1995). No significant additional effect of the X or Y variant promoter on 
susceptibility to HIV infection was observed. Structural and promoter alleles in studied 
cohort and other populations are shown in Tables 3.15 and 3.16.
Table 3.8 MBL-2 structural and promoter alleles in the studied group
MBL-2
genotype
All (n==128) 
n(%)
African (n=101) 
n (%)
YA/YA 64 (50 ) 47 (46.5)
YA/XA 33 (25.8 ) 26 (25.7)
XA/XA 2 (1.6) 1 (1.0)
YA/YO 18(14.1) 17(16.8)
XA/YO 5 (3.9) 4 (4.0)
YO/YO 6 (4.7) 6(5.9)
3.4.3 MBL and disease status
The relationship between MBL-2 genotype and disease status was examined. The 
immunological and viral markers in all patients were analysed and documented at the 
time of recruitment. There was no significant difference in HIV viral load or immune 
phenotype between patients with a wild type genotype or with one or more variant MBL- 
2 alleles (Table 3.9).
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Table 3.9 Correlation between MBL-2 genotypes, immunological and viral 
characteristics in HTV-1 infected children
Immunological 
markers (x lOV L)*
MBL-2 wild- type 
alleles ( n= 99)
MBL-2 variant alleles 
( n= 29) P-values
CDS T cells 1.970 (1360-2440) 1660(1265-2315) 0.24
CD4 T cells 670 (400-960) 540 (350-690) 0.33
CD8 T cells 1090 (820-1430) 1030 (620-1435) 0.56
Viral markers
HTV-1 RNA copies x
io ’ ' l
3900 (50-24 900) 1300 (50-19 541) 0.52
* Values in median (IQR), Mann-Whitney Test. P values < 0.05 indicate significance.
Similarly, when the MBL-2 genotype was analysed with respect to the CDC clinical 
classification no obvious differences were observed (chi-square test; p=0.14); (Table 
3.10).
Table 3.10 Distribution oi MBL-2 genotypes in CDC paediatric clinical categories
MBL-2
genotypes
Patients, 
n (%)
CDC A 
n (%)
CDCB 
n (%)
CDCC 
n (%)
YA/YA 64 (50.0) 23 (59.0) 23 (39.7) 18(58.1)
YA/XA 33 (25.8) 8 (20.5) 18(31.0) 7 (22.6)
XA/XA 2(1.6) 0 2(3.4) 0
YA/YO 18(14.1) 7 (17.9) 7(12.1) 4 (12.9)
XA/YO 5(3.9) 1(2.6) 2(3.4) 2 (6.5)
YO/YO 6(4.7) 0 6 (10.3) 0
Total 128(100) 39(100) 58(100) 31(100)
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However, when patients were classified according to their age-specific CDC CD4+ T 
cells immunological categories, patients in categories 2 and 3 (< 25% CD4+ T cells) 
were more likely to have MBL-2 variant alleles (chi-square test; p= 0.01; Table 3.11).
Table 3.11 Distribution oi MBL-2 genotypes in CDC Immunological categories
MBL-2
genotypes
Patients, 
n (%)
CD4 category 1 
(> 2 5 % ), 
n (%)
CD4 category 2 
(15- 24 %), 
n (%)
CD4 category 3 
(< 15 % ), 
n (%)
YA/YA 64 (50) 45 (58.4) 18(39) 1(20)
YA/XA 33 (25.8) 17(22.1) 14 (30.4) 2(40)
XA/XA 2(1.6) 1 (1.3) 0 1(20)
YA/YO 18(14.1) 11(14.3) 7(15.2) 0
XA/YO 5 (3.9) 1 (1.3) 4(8.7) 0
YO/YO 6(4.7) 2 (2.6) 3(6.5) 1(20)
Total 128 (100) 77 (100) 46 (100) 5 (100)
From these results it would appear that MBL deficiency is more frequent in patients with 
severe disease as assessed by CD4+ T-cells status. To examine these fiirther, patients 
who were classified as LTNPs were analysed.
3.4.4 MBL and Long Term Non-Progression in HIV infected children
HIV infection doesn’t inevitably lead to the development of AIDS (Levy et al, 1993). 
While the majority of HIV infected individuals progress to AIDS, a minority of patients 
do not show signs of disease and can maintain a stable CD4+ T cells count for at least 10 
years of infection. These patients are known as LTNPs (Vigano et al, 1997).
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The studied HIV population was divided into three groups: LTNPs (n=10), ARTN 
(n=35) and HAART (n=83). The characteristics of the patients in therapy groups are 
shown in Table 3.12.
Table 3.12 Detailed characteristics of the HIV-1 infected patients in therapy groups
LTNPs ARTN HAART P-
values
n(% ) 10(7.81) 35 (27.34) 83 (64.84) 0.32
Males/females 6/4 15/20 43/ 40 0.54
Age (years) 9.72 (8.25-13.12) 7.79 (5.76-10.97) 9.10(5.64-12.74) 0.21
CD4 T cells 545 (337-657) 500 (320-830) 690 (412-980) 0.22
CDS T cells 1070 (885-1407) 1160 (930-1620) 1060 (730-1350) 0.36
HIV-RNA 
copies X 10^/ L
4.98 (0.049-21.12) 21.38(8.6-40.4) 0.08 (0.049-6.08) 0.0001
Values in median (IQR), Kruskall-Wallis test, f-values <0.05 indicate significance.
LTNPs were found to have CD4+ and CD8+ T cell counts in the same range as that of 
subjects who were ARTN and HAART. The HIV-RNA viral load in LTNPs was 
significantly lower than that observed for the ARTN group (p< 0.05).
Tables 3.13 and 3.14 represent MBL genotype and phenotype analyses in this HIV 
cohort.
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Table 3.13 MBL-2 structural and promoter alleles in therapy groups
MBL-2
genotype
n(% ) LTNPs,
n(% )
ARTN,
n(% )
HAART, 
n (%)
YA/YA 64 (50) 2(20) 21(60) 41 (49.4)
YA/XA 33 (25.8) 7(70) 5 (14.3) 21 (25.3)
XA/XA 2(1.6) 0 1 (2.9) I (1.2)
YA/YO 18(14.1) 1(10) 5 (14.3) 12(14.5)
XA/YO 5 (3.9) 0 I (2.9) 4(4.8)
YO/YO 6(4.7) 0 2(5.7) 4 (4.8)
Total 128 (100) 10(100) 35 (100) 83 (100)
In children on HAART, the prevalence of MBL-2 gene mutations was higher than in other 
groups; HAART vs. LTNPs (p= 0.3); HAART vs. ART (p= 0.2); ART vs. LTNPs
(p=0.8).
Of the ten patients classified as LTNPs, only, one showed an MBL-2 mutation (A/D). 
Interestingly, this patient had an MBL level of 61Ing/ ml. Overall, the proportion of 
MBL-2 genotypes was not significantly different between the groups: LTNP-s, ARTN and 
HAART (Chi- square test; p= 0.17).
Table 3.14 Concentrations of serum MBL in the therapy groups (p=0.57, 
Kruskall Wallis test)
MBL serum levels 
( ng/ ml)
LTNP 
(n= 10)
ARTN 
(n =35)
HAART 
( n= 83)
Median ( ng/ ml) 2 991 2 005 2416
IQR 1517-3926 771-3929 1101-4937
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Normal range of MBL serum concentrations were maintained in the LTNPs (IQR, 1517- 
3926 ng/ ml) group. In comparison, MBL serum concentration assigned as low (MBL < 
300 ng/ ml), intermediate (MBL between 300 and 1300 ng/ ml), and normal (MBL > 
1300 ng/ml) was observed in 9 (10.8%), 13 (15.7%), and 61 (73.5%) of 83 HIV-1 
infected children who were receiving HAART. This proportion of MBL phenotypes was 
consistent with MBL genotype analysis.
In conclusion, 10 patients were classified as being LTNP. Only one of these patients had 
an MBL-2 gene mutation, suggesting that wild type MBL may contribute in maintaining 
the disease status in this group of patients. Normal MBL serum concentration in the 
LTNPs adds further support to our hypothesis.
3.4.5 HIV disease and MBL levels
The relationship between MBL levels and genotype was explored. Serum MBL levels 
were significantly related to MBL-2 genotype (p< 0.001). Fig 3.1 shows the correlation 
of serum MBL levels to MBL-2 genotype in all studied patients (Figure 3.1). To further 
investigate the role of MBL in HIV disease status MBL levels were analysed in relation 
to the CDC clinical and immunological categories. No significant differences in MBL 
levels were found between the groups when classified according to their CDC clinical 
status (p=0.45). Similarly, no significant difference in MBL levels was found between 
the groups when classified according to their CD 4+ T cells immunological categories 
(p=0.12; Figure 3.2). However, interestingly higher levels of MBL were observed in 
patients within the CD4+ T cells category 3 (CD4+ T cells< 15%) group when compared 
with category 1 and 2 (Figure 3.2).
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Figure 3.1 Correlation of serum MBL levels to MBL-2 genotype in paediatric HIV 
infection (p< 0.001). Box-whisker plot of MBL serum concentrations (ng/ml) in HIV- 
infected children. The boxed area represents 50% of values. The thick line inside the box 
represents the median value. Whiskers are 10-th and 90-th percentiles. Outliers are open 
circles.
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Figure 3.2 Serum MBL levels in patients classified according to CDC 
immunological categories of HIV infection. CDC Category 1, n= 76; Category 2, n= 
46; Category 3, n= 5; (Kruskal-Wallis; P= 0.117). Box-whisker plot of MBL serum 
concentrations (ng/ml) in HIV-infected children. The boxed area represents 50% of 
values. The thick line inside the box represents the median value. Whiskers are 10-th 
and 90-th percentiles. Outliers are open circles.
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3.5 DISCUSSION
s
In the present study we have investigated the potential role of MBL in a paediatric HIV- 
1 infected cohort from the HIV Family Clinic at GOSH, London, UK. Most (79 %) of 
the children enrolled in our cohort at GOSH were of sub-Saharan African origin. We 
analysed MBL genotype frequencies in the whole cohort and we looked separately at the 
MBL genotype distribution in African children. Appropriate ethnically matched control
group was not available. Therefore we used other MBL published data from studies
performed in Africa to compare our results. These studies are summarized in Tables 3.15 
and 3.16 and discussed in more details.
3.5.1 MBL and HIV infection in African populations
From previous studies it is known that MBL genotype frequencies distribution varies not 
only between continents and different populations but also within the continent of Africa 
(Lipscombe et al, 1996). The analysis of frequencies between different African 
populations by geographical location (Tables 3.15 and 3.16) showed highly significant 
differences in MBL gene distribution, both wild type (WT) and gene mutation (A/ O, 
0 /0 ) between Gabon population and Ghanaians from West Africa, (p<0.0001). 
Similarly, there was significant difference in MBL gene distribution between Soweto 
population. South Africa and Ghanaians, West Africa, (p<0.0001).
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Table 3.15 MBL exon-1 genotype frequencies in HIV-1 infected patients and other populations
MBL
gen
Studied group 
Total
n= 128 (%)
Studied 
African 
n=101 (%)
Gabonese
m v-
uninfected 
n= 120 (%)
Gabon
Total
n=188(%)
Soweto 
South 
Africa 
n=168 (%)
Ghanaians 
West Africa 
n= 551 (%)
Oxford 
controls 
n= 353 (%)
A /A 99 (77.3) 74 (73.3) 80 ( 66.7) 124 (66.0) 109(64.9) 257 (46.6) 213 (60.3)
A/B 2(1 .6) 2 (2.0) 4(3.3) 4(2.1) 4(2.3) 3(0.5) 73 (20.7)
A/C 17(13.3) 16(15.8) 34 (28.3) 53 (28.2) 50 (29.8) 234 (42.5) 7(2.0)
A/D 4 (3.1) 3(3.0) 2(1.7) 3(1.6) 0 0 42(11.9)
A/O 23 (18.0) 21 (20.8) 40(33.3) 60 (31.9) 54 (32.1) 237 (43.0) 122 (34.6)
B/B 0 0 0 0 0 0 10 (2.8)
C/C _ 4(3.1) 4 (4.0) 0 2(1.06) 5(3.0) 56(10.2) 0
D/D 0 0 0 0 0 0 7(2.0)
B/C 0 0 0 2(1.06) 0 1 (0.2) 1 (0.3)
C/D 2(1.6) 2(2.0) 0 0 0 0 0
0 / 0 6(4.7) 6(6.0) 0 4(2.1) 5 (3.0) 57 (10.4) 18 ( 5.1)
Table 3.16 MBL structural and promoter polymorphisms in the studied cohort and other African populations
MBL
Genotype
Studied group 
(All)
n=128(%)
Studied group 
(African) 
n= 101 (%)
Ghanaians 
n= 551(%)
Mozambique 
n= 154 (%)
YA/YA 64 (50 ) 47 (46.5) 171(31) 66 ( 42.86)
YA/XA 33 (25.8 ) 26 (25.7) 81 (14.7) 21 ( 13.64)
XA/XA 2 (1.6) 1 (1.0) 6 (1.1) 2 ( 1.29)
YA/YO 18(14.1) 17(16.8) 189 (34.3) 41 ( 26.62)
XA/YO 5 (3.9) 4 (4.0) 47 (8.6 ) 14 ( 9.09)
YO/YO 6 (4.7) 6(5.9) 57(10.4) 10 ( 6.49)
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Additional comparisons between different African populations and Oxford control group 
were carried out (Roy et al, 2002). There was a highly significant difference in WT 
MBL gene distribution between Ghanaians and the Oxford population, (p< 0.0001). The 
fi-equency is 257/551 (46.6%) for Ghanaians whilst this is higher 213/353 (60.3%) for 
Oxford controls. There is also evidence of a difference in MBL gen A/O genotype 
distribution between these studies populations, (p=0.01). The fi-equency is 237/551 
(43%) for Ghanaians while this is lower 122/353 (34.6%) for the Oxford population. 
When compared differences in MBL genotype 0 /0  between Ghanaians and Oxford 
significant difference was also found, (p< 0.01). The frequency is 57/551 (10.3%) for 
Ghanaians while this is lower 18/353 (5.1%) for Oxford control. Other relations between 
studied Afi-ican and Oxford populations were considered. These are not of statistical 
significance such as comparing Gabonese or Soweto, South Africans with Oxford 
population.
Studied population of Afiican HIV-infected children (n=101) was compared with other 
Afi-ican cohorts and Oxford control. There is some evidence of difference in MBL 
genotype A/O distribution in our cohort of patients and Africans. There is a difference 
between our cohort and Gabonese HIV uninfected population, (p=0.04). The frequency 
is 21/101 (20.8%) for our cohort while this is higher 40/120 (33.3%) for Gabonese. 
Similarly, there is some evidence in MBL A/O genotype distribution between our cohort 
and Soweto, South African, (p=0.04). The fi-equency is higher 54/168 (32.1%) for 
Soweto, South Afiica. We looked at other relations in WT and MBL homozygous 
genotype distribution and no significant difference was found. Interestingly, there is
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strong evidence of difference in MBL WT and genotype A/ O distribution between our 
studied cohort and Ghanaians (p< 0.0001), and Oxford (p=0.01).
The WT (A/A) frequency is 74/101 (73.3%) for our cohort while is lower 257/551 
(46.6%) for Ghanaians and 213/353 (60.3%) for Oxford. The A/O genotype distribution 
varies significantly between our studied African group and Ghanaians and Oxford 
control. The frequency is 21/101 (20.8%) for our cohort while this is higher 237/551 
(43%) for Ghanaians and 122/352 (34.6%) for Oxford control. There was no significant 
difference in MBL 0 /0  genotype distribution between our cohort of patients and 
Ghanaians or Oxford.
The additional effect of X/Y polymorphism in MBL gene (Table 3.16) on HIV status in 
our cohort of HIV infected children has been compared with other African population 
with known MBL gene polymorphisms including X/ Y genotype. There is difference in 
MBL genotypes: YA/ YA, YA/ XA, and YO/YO distribution between studied HIV 
infected children and Ghanaians (p<0.01). The YA/ YA MBL genotype frequency is 
47/101 (46.5%) for studied group while this is lower 171/551 (31%) for Ghanaians. The 
YA/XA MBL genotype frequency is 26/101 (25.7%) for studied group while this is 
lower 81/551 (14.7%) for Ghanaians. The frequency for YA/ YO genotype in studied 
group is 17/101 (16.8%) while this is higher 189/551 (34.3%) for Ghanaians. Similar 
relations were studied between our cohort of HIV infected children and Mozambique 
population. Amongst studied MBL genotypes, there only significant difference was 
observed within MBL genotype YA/ XA, (p=0.01). The frequency is lower 21/154
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(13.6%) for Mozambique when compared to studied population (25.7%). Other 
comparisons were not of significance.
In addition, the optional control group for comparison would be an ethnically and age 
matched group with known HIV status who were simultaneously studied for MBL 
genotype and phenotype at the same time and in the same laboratory using the same 
comparable methods of MBL detection. The HIV status of published paediatric studies 
listed in Table 3.15 is unknown except for the Gabonese study and a British Caucasians, 
which were adults’ studies. Other studies listed in Table 3.16 were all paediatric studies. 
The Soweto control group included infants aged 1-12 months requiring hospitalization 
for lower respiratory tract infection caused by respiratory syncytial virus (RSV) (n= 55) 
and 113 age-and-sex ethnically matched controls (Kristensen et al, 2004). The second 
control population included children between 0 and 13 years old from Ghana (n=323) 
admitted with P. falciparum malaria to hospital and healthy children between 5 and 15 
years of age with or without detectable P. falciparum (n=228) from a local area (Garred 
et al, 2003). One must emphasize that the HTV status of these paediatric populations is 
unknown.
3.5.2 The potential role of MBL in HIV infection in children
The frequency of MBL gene mutations in our cohort was 26.8 % in total (including 
heterozygous and homozygous). Interestingly, MBL mutations were found to be 
underrepresented in our patient cohort when compared to the other cohorts (Tables 3.15, 
3.16). Lack of a control ethnically matched group with known MBL genotype status is a
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limitation of the present study. The explanations as to why we observed lower 
frequencies of MBL variant alleles in our cohort of patients are unknown. However, if 
confirmed, it may suggest that MBL deficiency may have a protective role in HIV 
infection. Furthermore, the ethnic selection in our study group may help to explain the 
difference in findings between the previously published paediatric studies in Africa. The 
majority of children in our cohort are of Afi*ican origins who have survived before 
arrival to the UK as the median age of the studied group was 8.9 years. They had been 
diagnosed with HIV at different clinical stages (progression) of the disease. We suspect 
that some of the Afiican children with advanced HIV disease or AIDS presumably 
associated with variant O allele could have life expectancy (duration of survival) shorter 
than those with wild-type alleles and consequently died in early life with AIDS before 
being diagnosed or prior to introduction of antiretroviral therapy (ART). In our Family 
Clinic at GOSH 41 children died between 1991 and 1996. In contrary, only 16 children 
died between 1997 and 2004 when ART became available. If this hypothesis is 
confirmed, MBL deficiency must have a negative effect on disease progression and 
subsequent death.
Despite impressive in vitro data on MBL and HIV interaction initiated since 1989 
(Ezekowitz et al, 1989, Haurum et al, 1993, Saifuddin et al, 2000, Spear et al, 2003, 
Ying et al, 2004, Marzi et al, 2007), epidemiological studies have been less conclusive. 
There is a broad agreement that MBL deficiency, assayed by genotype or phenotype, is 
associated with a greater susceptibility to HIV acquisition. MBL deficiency increased 
the acquisition of HIV infection by 3 and 8 fold (Garred et al, 1997a; Garred et al, 
1997 b; Nielsen et al, 1995; Prohaszka et al, 1997) and increased the risk of vertical
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transmission from infected mothers to their offspring (Boniotto et al, 2000; Boniotto et 
al, 2003).
Few studies have investigated the impact of MBL during paediatric HIV infection. The 
presence of the mutated MBL allele was significantly more frequent in HIV infection in 
perinatally exposed Brazilian children than in unexposed uninfected children (Boniotto 
et al, 2003). Similar findings suggesting that MBL deficiency predisposes to increased 
susceptibility to HIV infection in adults has also been reported (Garred et al, 1997a). 
HIV-infected patients were more likely to be homozygous for MBL variant alleles. 
Another study performed by the same group in an African population suggested that 
MBL mutations occurred more frequently in HIV infected patients when compared to 
uninfected controls (Garred et al, 1997b). Prohaszka et al, 1997 demonstrated lower 
serum concentrations of MBL in HIV- seropositive patients compared with negative 
controls, a finding was also confirmed by Nielsen et al, 1995.
Other studies, however, did not find similar associations. For example, Pastinen et al, 
(1998) found that high MBL levels which correspond to wild-type alleles were 
significantly associated with acquiring HIV. Senaldi et al, found MBL levels to be 
higher in HIV patients than controls (Senaldi et al, 1995). While another study found 
similar MBL genotype frequencies in Colombian HIV-infected and control individuals 
and further no link between MBL levels and HIV transmission was established (Malik et 
al, 2003). Interestingly, the recently published study by Garcia-Laorden and co-workers 
has found a decreased frequency of MBL variants in HFV infected population (Garcia-
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Laorden et al, 2006) which corresponds to our finding. The majority of studies were 
performed before the era of ART.
A clear difference in natural HIV progression between adults and children has been 
observed with respect to transmission, pathogenesis and clinical manifestations (Scott et 
al, 1984; Ebrahim et al, 1991). In our population study ~23 % of HIV- infected 
children had an MBL polymorphism and of these 69% were receiving combination 
antiretroviral (HAART) therapy. In contrast, only 10% HIV positive children defined as 
LTNP and 22.8 % ARTN exhibited MBL polymorphism. We found that proportion of 
MBL genotypes were not significantly different between groups on different therapeutic 
regimens. It is most likely that due to the lack of greater number in our cohort of LTNPs 
that no significant difference in MBL genotype distribution was noted between the 
various groups on different therapeutic regime. Unfortunately, no information on disease 
progression was available for the studied Brazilian HIV infected children, but the 
findings of Boniotto and co-workers with respect to an Italian paediatric population 
seem to confirm a role for MBL in HIV disease progression (Boniotto et al, 2000). 
Other study by Amoroso and colleagues showed that children with rapidly progressing 
disease are more likely to have MBL alleles (codon 54) therefore MBL mutation confers 
a relative risk for rapid progression to AIDS (Amaroso et al, 1999). Our hypothesis of 
normal MBL levels in LTNPs is consistent with other studies which showed no 
reduction in MBL serum concentration in LTNPs with HIV infection (Maas et al, 1998, 
Hundt et al, 2000). These combined results suggest that wild type MBL may be a 
protective host factor in HIV infection. Furthermore, the ethnic selection in our study 
group may help to explain difference in findings between the previously published
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paediatric studies. The majority of children are of African origin who survived before 
arrival to the UK. We suspect that some of the African children with advanced HIV 
disease or AIDS presumably associated with variant O allele could have life expectancy 
shorter than those with wild-type alleles and consequently died in early life with AIDS 
before being diagnosed or treated.
In conclusion, HIV-infected children with MBL polymorphism exhibited a trend 
towards an increase in the rate of disease progression. The frequency of MBL genotypes 
were higher in children on HAART compared with LTNP or ARTN individuals. The 
detection of MBL mutations may be a useful predictor to identify children with delayed 
disease progression who, consequently, may not require immediate antiretroviral 
treatment.
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CHAPTER 4
THE ROLE OF MBL IN SUSCEPTIBILITY TO 
INFECTION IN PRETERM NEONATES
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4.1 INTRODUCTION
Despite advances in perinatal care, neonatal infection remains an important cause of 
morbidity and mortality, particularly among very low birth weight (VLBW) preterm 
infants (Stoll et al, 2002; 2005). Reported rates of infection vary considerably, but may 
be higher than 20% in low gestational ages (Stoll et al, 2005). It would appear that this 
figure has not changed dramatically in the last decade. Neonatal deaths attributed to 
sepsis are still considerable with mortality rates as high as 36% in Gram negative sepsis 
and 32% in fungal sepsis (Stoll et al, 1996; Karlowicz et al, 2000).
Numerous factors are responsible for the high rate of infection in this patient population. 
Neonates of low gestational age and birth weight are particularly at risk of infection, in 
part due to intensity of supportive care required, which include mechanical ventilation, 
parenteral feeding and the requirement for prolonged intravenous access. In addition, 
there are immunological reasons why infection occurs. IgG concentration in preterm 
neonates depends on active placental transfer and increases with gestational age (Landor 
1995). The absence of passively derived maternal antibody such as that directed against 
Group B Streptococcus appears to be important (Klegerman et al, 1983, Sandberg et al, 
2000, Luck et al, 2003). Indeed premature neonates of less than 32 weeks of gestation 
have fetal IgG concentrations of less than 50 % of maternal levels (Christensen et al, 
1984; Lin et al, 2001). In addition, many elements of the acquired immune system are 
also either low or function sub-optimally (Table 4.1). It is in these circumstances, that 
the innate immune system may be particularly important in providing protection against 
infection.
4.1.1 The potential role of MBL in early life
A number of studies have now looked at MBL in the neonatal setting (summarised in 
Table 4.2). Terai and co-workers reported that in term neonates, MBL levels increased 
during the first five days after birth (Terai et ah, 1993). Thiel showed that MBL levels at 
term were only a third of those seen at 3 months (Thiel et al, 1995). It would appear 
fi*om a number of subsequent publications that MBL levels are lower in preterm than 
term neonates and is related to gestational age rather than birth weight (Lau et al, 1995; 
Hilgendorff et al, 2005; Frakking et al, 2006). It is currently unknown whether MBL 
levels play a clinical role in preterm neonates.
4.2 AIMS
The aims of the study presented in this chapter were:
1) To investigate the impact of MBL genotype/ phenotype on susceptibility to 
infection in preterm neonates during the first month of life.
2) To assess the developmental profile of MBL levels in relation to genotype, 
gestational age and birth weight.
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T LYMPHOCYTES and ANTIGEN PRESENTATION
Class IIMHC molecule Expression by monocytes and B cells. Variable data depending 
upon report. Expression either similar or reduced.
Keever ef a/., 1995 
Clerici et a/., 1993
Interactions between T 
cells and Antigen- 
Presenting Cells (AFC)
T cell surface molecules: CD2, LFA-1(CD1 la-CD18) 
CD45R0, ICAM-1 (CD54), CD40 ligand lower on neonatal T 
cells.
Reduced or delayed T cells responses.
Reduced function of dendritic cells in neonates
Hunt et a/., 1994 
Nelson and Holt; 1995
T cell cytokine 
responsiveness
Cytokine deficiency of neonatal T cells Ehlers & Smith; 1991; Lewis et al, 1991; 
Matsuda et al, 1996; Garcia et al, 2000
T cell-mediated 
cytotoxicity
Neonatal T cells moderately less effective than adults T cells Rayfield et al, 1980; Harris et al, 1994; 
Risdon et a/., 1994
B CELLS and IMMUNOGLOBULINS
B cells Neonatal CD5-B cells reduced expression of adhesion 
molecules including CDl 1, CD44, CD54 (ICAM-1), CD62- 
L(L-selectin)
Parra et n/., 1996
Immunoglobulins Production of Immunoglobulin by neonatal activated B cells 
similar to adults antigenically naive B cells or reduced 
Fetal B cells (mid-gestation )
Nonoyama et a/., 1995; 
Durandy 1995;
Natural Killer (NK) 
Cells
Fetal and neonatal NK cells reduced
- expression of CD2, CD56, CDS?
- reduced cytotoxic function
- reduced cytolytic activity (NK cells, CD56-, 50 % at birth)
Merrill et û/., 1996 
El-Sameeaeta/., 2004
PHAGOCYTES
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Neutrophils Present at birth, the numbers of circulating neutrophils 
increase sharply in term and preterm neonates 
Preterm neonates have limited ability to accelerate neutrophil 
production in response to infection-depleted neutrophil 
storage pool.
Migration: adhesion of neonatal neutrophils under resting 
conditions is normal, whereas adhesion of activated cells is 
deficient (40 -50 % less)
- deficiency in L-selectin, p integrins, LFA, ICAM
- chemotaxis preterm and term neonates impaired 
Phagocytosis of bacteria by neutrophils from preterm 
neonates reduced
Microbicidal activity of neonatal neutrophils decreased
MomoQ et al, 1979
Squire gf a/., 1979 
Christensen gf aZ., 1980
Anderson ef a/., 1981; 1984; 1990; 1991 
Smith et al, 1990; Raghunathan et al, 
1982; Klein et al, 1977; Falconer et al, 
1995; Fujiwara et al, 1997; Anibruso et 
al, 1979; Strauss et a/., 1980;
Levy et al, 1999; Arinola et al, 2003; 
Koenig et al, 2004
Monocytes Delayed response (chemotaxis) in term and preterm neonates 
Capacity to produce cytokines may be reduced in term and 
preterm neonates
Sheldon and Cadwell 1963 
Hallwirth et al, 2002; 2004.
Complement Preterm neonates have a clearer and consistent decrease in 
both classic and alternative pathway activity.
The levels of most complement protein increase postnatally 
and approach adult values by 6-18 months of age
Miyanoeta/., 1991 
Arinola et al, 2003
Fibronectin Diminished levels in neonates, particularly in preterm Gerdes et al, 1983; Barnard and Arthur 
1983, Yoder et al, 1983
C-Reactive Protein Serum levels in preterm and term neonates appear to be 
similar to that of adults
El-Sameea et al, 2004
MBL,
Lipopolysaccbaride- 
Binding Protein, 
Surfactant Apoproteins
MBL is subject of this thesis and described in details.
Mice deficient in SP-A are more susceptible to pulmonary 
infection. The role of SP-D unknown.
Surfactant deficiency maybe one factor in the greater risk of 
the preterm neonate for pulmonary infections.
LPS-binding protein, a deficiency in neonatal protein, that 
facilitates the response of monocytes to lipopolysaccharide
Cohen et a/., 1995 
Yoshio et al, 2004
Table 4,1 Developmental Immunology of Neonate
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Study Patients Measurements Assay MBL levels (mean ) 
(ig/ml
Outcome measures
Terai et al, 
1993
Term neonates 
(n=27)
MBL levels after birth 
and 0-5 days
ELISA birth 1.07
5 days of life MBL=2.48
MBL present at birth and 
increase in MBL levels 
within 5 days of life
Malhotra 
et al, 1994
MBL levels from 
amniotic fluid
MBL levels in relation 
to gestational age 
(26-41 wk)
ELISA <35 weeks of gestation 
MBL=0.34
>35 weeks of gestation 
MBL=1.07
significant increase in MBL 
levels from 32 weeks of 
gestation towards term
Thiel et al, 
1995
Term neonates 
(n=40)
Preterm neonates 
(n=10)
MBL levels measured 
during the 1®* year of 
life:
0, 3, 6, 9, 12 months. 
Preterm MBL at birth 
and at 10 wks of life.
ELISA Term neonates 
at birth MBL=1.3 
3 months MBL= 2.6 
6 months MBL=2.5 
9 months MBL=2.6 
12 months MBL=3.1
MBL levels increased after 
birth in preterm and term 
neonates.
MBL increased in the first 
10 weeks of life and further 
increased during the 1®^ year 
of life.
Lau et al, 
1995
Preterm neonates 
(n=168 )
Term neonates 
(n=146)
Longitudinal study 
MBL levels in preterm 
and neonates.
ELISA Gestational age (mean) 
25 weeks MBL=0.5 
Postnatal age 20 weeks 
MBL=1.07
MBL levels increased with 
gestational age.
Hilgendorff 
et al, 2005
Preterm neonates 
(n=47) and Term 
neonates (n=19)
MBL levels in relation 
to gestational age (24- 
31 wk)
< 32 weeks of gestation 
MBL=0.75
Term neonates 
MBL=3.17
MBL levels lower in 
preterm neonates <32 wks 
of gestation compared to 
term.
Frakking et 
al, 2006
Preterm neonates 
(n=69)
Term neonates 
(n=16)
MBL levels measured 
at birth and during 3 
weeks of life (n=26)
ELISA Preterm MBL =0.98 
Term MBL=1.2
MBL levels lower in 
preterm neonates. Low 
MBL levels related to lower 
gestational age. MBL levels 
increased over 3 weeks.
Table 4.2 List of published studies investigating the potential role of MBL in early life
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4.3 PATIENTS AND METHODS
4.3.1 Patients
One hundred sixty six preterm neonates of gestational age less than < 3 7  weeks (age 
estimated from obstetrical data including last menstrual period and confirmed by 
ultrasound as well as by clinical examination of newborn according to the Ballard Score) 
were prospectively recruited for this study between September 2002 and June 2005. 67 
were from the Neonatal Intensive Care Unit at University College London Hospitals 
(UCLH), NHS Trust, London, UK and 99 were from Polish Mother Memorial Hospital- 
Research Institute (PMMH-RI), Lodz, Poland. An additional cohort of 52 term neonates 
was also recruited to the study from Poland. Ethical approval was obtained for the study 
in both institutions and written parental consent was obtained prior to patient enrollment. 
Neonates with major congenital abnormalities or requiring surgical intervention were 
excluded.
4.3.2 Sample collection: MBL genotype and phenotype
All neonates included in the study had blood taken for MBL phenotyping and 
genotyping. Blood was collected on days 1-3, 7-10, 14-18 and 27-30 after birth and 
serum isolated and stored at - 80°C for future MBL analysis by ELISA (Antibody Shop/ 
Statens Serum Institute, Copenhagen, Denmark). A total of 397 serum samples were 
collected longitudinally for measuring MBL protein levels, on days: 1-3 (n=130), 7-10 
(n=l 13), 14-18 (n=91) and 27-30 (n=63). Whole blood was also obtained for MBL 
genotyping. Samples were collected into potassium EDTA and frozen at -80°C until
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required. DNA was isolated from whole-blood samples using a commercial kit (QIAamp 
DNA, blood mini kit, Qiagen, Crawley, UK) according to manufacturer’s instructions.
In 158 preterm neonates (97 Polish and 61 British) MBL-2 genotyping for both structural 
and promoter polymorphisms was successfiilly determined. In 8 neonates a genotyping 
sample was either not obtained (n=5) or was insufficient (n=3) for MBL genotyping. 
The genetic variants within exon 1 of the MBL gene at codon 52 (D), 54 (B) and 57 (C) 
were determined by polymerase chain reaction (PGR) followed by heteroduplex analysis 
utilising polyacrylamide gel electrophoresis. Wild type alleles were denoted as A and 
variant alleles as O. Promoter polymorphisms at -221 (X/ Y) of the MBL gene were also 
determined using a similar method. The three MBL-2 structural gene mutations, B, C, 
and D are in linkage disequilibrium with the promoter region polymorphism X/Y, so that 
only Y associates with variant alleles.
4.3.3 Infection
Each neonate was followed up during the study period (days 0 to 30) for evidence of 
infection. Blood cultures were performed when infection was suspected. Definitive 
sepsis was diagnosed if they had the combination of a positive blood culture and clinical 
and/or laboratory evidence of sepsis. Clinical markers of sepsis included poor circulation 
(pallor, decreased perfusion, hypotension, tachycardia or bradycardia), increased oxygen 
requirement or ventilation parameters, temperature instability, lethargy or irritability, 
abdominal distension, feeding intolerance and jaundice. Laboratory markers included 
abnormal leukocyte count ( < 5000 x 10  ^cells/ L or > 25 000 x 10  ^cells/ L cells at 
birth, > 30 000 x 10  ^cells/ L at 12-24 hours of life, >21 000 x 10  ^cells / L after 48
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hours of life), increased immature-to-total neutrophil ratio (I/T ratio) (> 0.2) and / or 
ratio between bands and segmented neutrophils >0.3, low platelet count ( < 150 000 x 
10  ^ cells / L) and raised C-Reactive Protein (GRP). Positive blood cultures in the 
absence of clinical or laboratory evidence of sepsis were considered to be contaminants 
and excluded from the study. Neonates were ‘presumed’ to have sepsis if they had 
clinical or laboratory evidence of sepsis but without positive blood cultures. The clinical 
data was collected prospectively and a diagnosis of sepsis was recorded. However to 
provide a more consistent evaluation of this diagnosis, the designation of a sepsis 
diagnosis was made by clinicians (including Research Fellow A.D.) who reviewed the 
notes retrospectively. During assessment they were blinded from the MBL data. In the 
UK cohort the duration of antibiotic therapy used in the first 30 days of life was also 
recorded as a proxy marker of sepsis. This information was not recorded in the Polish 
cohort.
4.3.4 Methods and Statistical analysis
The detailed description of laboratory methods used for assessing MBL genotype and 
phenotype are presented in Chapter 2. To ease interpretation of the relationship between 
MBL genotypes and clinical/microbiological data, the 3 variant alleles (D=codon 52 
variant, B=codon 54 variant, C=codon 57 variant) were grouped together and denoted as 
an O with A indicating a normal or wild type allele. Patients were classified according to 
their MBL exon-1 mutations as wild-type (A/A), heterozygous (A/0), or homozygous 
(0/0). Genotype (or allele) frequencies were analysed by the Chi-square test. 
Differences between groups (MBL serum levels) were compared using the Mann-
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Whitney U Test (for two groups) or Kruskal-Wallis test (three or more groups). Changes 
in MBL levels were analysed using a mixed effect model that took into account 
correlations between repeated measurements within an individual (Laird and Ware 
1982). All models included an intercept for measurements performed on days 1-3, a first 
slope for the change to 7-10 days and then a second slope for the change from 7-10 days 
to the end follow-up. Then, the effect of the genotype, birth weight and gestational age 
at birth on baseline and evaluation of MBL levels were tested. In addition, the 
modification of the effects of birth weight or gestational age at birth due to genotype was 
checked through interaction terms. The analyses of the risk of sepsis according to MBL 
levels, birth weight and gestational age at birth were performed using logistic regression. 
Probability values were two-sided, and statistical significance was defined as p < 0.05. 
Analyses were performed with SPSS version 12.0 (SPSS, Inc, Chicago, IL, USA) and 
with SAS version 9.1 (SAS®, Cary, NC, USA).
4.4 RESULTS
4.4.1 Patients Characteristics
166 premature neonates (99 Polish and 67 British) were enrolled into the study. 158 
were included for further analysis (see below). Within this group, the median gestational 
age was 30 weeks (range 24-36 weeks) and the median birth weight was 1399 grams 
(range 510-2958 grams). 95 out of 158 (60%) neonates had a birth weight < 1500g and 
were classified as very low birth weight (VLBW) and 45 (28%) had a birth weight < 
lOOOg (extremely low birth weight, ELBW). 46 out of 158 (29%) were neonates of
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gestational age < 28 weeks, and 81 % of these were ELBW. There were no significant 
differences between the British and Polish cohorts in terms of sex (p=0.93), gestational 
age (p=0.39) and birth weight (p=0.37).
The detailed demographic characteristics are shown in Table 4.3.
Table 4.3 Demographic characteristics of preterm neonates in this cohort (n=158)
Characteristics British neonates 
n=61
Polish neonates 
n=97
Total 
n (%)
Ethnicity
White 27 97 124 (79)
Black 7 - 7 (4)
White& Black 7 - 7 (4)
Asian 8 - 8 (5)
Others/unknown 12 - 12 (8)
Sex
Female 27 44 71 (45)
Male 34 53 87 (55)
Gestational age, wk
<28 23 23 46 (29)
29- 30 7 25 32 (20)
>30 31 49 80 (51)
Birth weight, g
< 1000 (ELBW) 23 22 45 (28)
< 1500 (VLBW) * 37 58 95 (60)
> 1500 24 39 63 (72)
including neonates with ELBW (n=45)
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4.4.2 Analysis of MBL genotype
MBL-2 genotypes were successfully determined in 158 (97 Polish and 61 British) 
preterm neonates and 52 term neonates. Table 4.4 shows the frequency of MBL 
genotypes for the British and Polish neonates. There was no significant difference in the 
frequency of MBL genotypes between the two populations (p=0.44). The distribution of 
MBL genotypes was similar between neonates of different gestational age and birth 
weight (data not shown).
Table 4.4 Frequency of MBL exon-1 mutations
MBL Genotype Preterm neonates (n=158) Term neonates 
(n, %)British (n, %) Polish (n, %)
Wild type (A/ A) 36 (59.0) 67 (69.0) 34 (65.0)
Heterozygous (A/ O ) 23 (38.0) 27 (28) 18(35.0)
A/B 16 19 13
A/C 6 3 0
A/D 1 5 5
Homozygous (O/ O) 2 (3.0) 3(3) 0
B/B 0 3 0
B/C 2 0 0
Total 61(100) 97(100) 52 (100)
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In addition, neonates were analyzed according to their MBL gene polymorphism in the 
promoter region at position -221 (X/ Y). The results are presented in Table 4.5.
Table 4.5 Frequency of MBL exon-1 and X/ Y promoter polymorphisms
MBL Genotype Preterm neonates (n=158) Term neonates 
(n, %)British (n, %) Polish (n, %)
YA/YA 22(36.1) 34 (35.1) 14 (35.9)
YA/XA 14 (23.0) 29 (29.9) 9 (23.1)
XA/XA 0 4 (4.1) 2 (5.1)
YA/YO 17(27.8) 22 (22.6) 10 (25.6)
XA/YO 6 (9.8) 5 (5.2) 4 (10.3)
YO/YO 2 (3.3) 3 (3.1) 0
Total 61 (100) 97 (100) 39 (100)
4.4.3 MBL genotype and sepsis
Forty seven neonates from the 158 with known MBL genotypes (29.7 %) had a single 
positive blood culture during the study period which was associated with clinical or 
laboratory evidence of sepsis (definitive sepsis): 16 (26.2 %) were from the British 
cohort and 31 (31.9 %) were from the Polish population. Nine neonates had a second 
positive blood culture with Coagulase negative staphylococci {CONS) n=3; 
Enterobacter sp. n=l, Klebsiella sp. n=2, Candida albicans n=3. These were not 
included in the analyses. The organisms isolated during the first episode of sepsis are
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presented in Table 4.6. In both populations the majority of positive blood cultures were 
caused by CONS. Only five blood cultures were positive for Gram-negative organisms 
and one for Candida albicans. No significant association was found between definitive 
sepsis and MBL genotype for the neonatal population as a whole (p=0.46).
Table 4.6 Microorganisms associated with the first episode of sepsis.
The table shows the number of individual neonates in the studied cohort with positive 
blood cultures.
Organisms British Polish Total
Gram-positive 15 26 41
Coagulase negative Staphylococcus 13 22 35
Staphylococcus aureus 1 3 4
Group B Streptococcus 1 1 2
Gram-negative 1 4 5
Escherichia coli 0 1 1
Klebsiella sp. 1 0 1
Enterobacter sp. 0 1 1
Haemophilus influenzae 0 1 1
Corynobacterium macginleyi 0 1 1
Fungi 0 1 1
Candida albicans 0 1 1
Total 16 31 47
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Of the 47 positive blood cultures, 42 were from VLBW neonates. Of these, 17 had MBL 
variant alleles and 25 were WT. There were 53% (17/32) of the VLBW neonates with 
variant alleles who had a definitive sepsis compared to 39% (25/63) in the WT VLBW 
population and this just failed to reach significance (p=0.053). Analyses of the effect of 
MBL genotype, gestational age < 28 weeks and birth weight < lOOOg also did not show 
a statistically significant association with sepsis. Interestingly, 4 of the 5 patients who 
were found to be homozygous for MBL variant alleles had a definitive sepsis. There was 
no apparent relationship between MBL genotype and susceptibility to any specific 
micro-organism.
In total, 80 out of 158 (50.7 %) preterm neonates were diagnosed with sepsis. Of these, 
47 had definitive sepsis and 33 had presumed sepsis. 54.6% of neonates with MBL-2 
variants had sepsis compared to 48.6% with a wild type genotype (A/A), (Table 4.7). 
This was not significant (p=0.47, calculated by Chi-square).
Table 4.7 MBL genotype and rate of sepsis in preterm neonates (n=158)
MBL genotype-exonl Sepsis (n, %) No sepsis (n, %) Total
A/A 50 (48.6) 53 (51.4) 103 (100)
A/ O and O/ O 30 (54.6) 25 (45.4) 55 (100)
Total 80 (50.7) 78 (49.3) 158 (100)
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Of 95 neonates classified as VLBW, 69 (72.6%) had a septic episode, definitive or 
presumed. 27 out of 32 (84.3%) neonates with variant alleles had a septic episode 
compared to 42 out 63 (66.7%) with a wild type genotype. This just failed to reach 
significance (p=0.056). Table 4.8. Analyses of the effect of MBL genotype, gestational 
age < 28 weeks and birth weight < lOOOg also did not show a statistically significant 
association with sepsis, definitive or presumed.
Table 4.8 MBL genotype and sepsis in VLBW preterm neonates (n= 95); (p=0.056).
MBL genotype-exon 1 Sepsis (n, %) No sepsis (n, %) Total (n, %)
A/A 42 (66.7) 21 (33.3) 63 (100)
A/ 0  and 0 / 0 27 (84.3) 5 (15.7) 32 (100)
Total 69 (72.6) 26 (27.4) 95 (100)
4.4.4 MBL Phenotypic analysis
MBL levels at birth and throughout the 30 day study period were measured and related 
to MBL-2 genotype, gestational age and birth weight. 130 neonates had a sample taken 
within the first 3 days of life and 38 neonates had 4 samples collected (completed serial 
measurements). As expected, serum MBL levels were significantly related to MBL-2 
genotype (p < 0.001). MBL levels were found to be significantly lower in neonates bom 
at 30 weeks or less compared to term neonates (p<0.05), (Table 4.9).
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Table 4.9 MBL levels in relation to gestational age.
Matching MBL levels and genotypes Ifrom preterm (n=130) and term neonates (n=52) 
analysed from samples taken between 1 and 3 days after birth.
MBL- exon 1 
Genotype
MBL levels 
(1-3 days of life)
Gestation 
< 30 weeks
Gestation 
31-36 weeks
Gestation 
> 37 weeks
A/A Median (ng/ml) 2230 2473 2799
Range 423-5097 1023-4494 1288-5386
AJO and 0 /0 Median (ng/ml) 182 341 511
Range 28-816 17-940 124-793
MBL levels were also determined by postnatal age. Levels increased between the 1-3 
day sample and the 7-10 day sample (Figures 4.1 and 4.2). The increase between the 
first two samples was larger in WT neonates (+243 ng/ml/day 95% Confidence Interval 
[Cl] =+196; +291) than in neonates with MBL mutations (+43 ng/ml/day [Cl] =-17; 
+103, p <0.001). This increase remained stable for the subsequent 2 samples.
In WT neonates, baseline MBL levels were significantly lower in babies bom at 28 
weeks of gestational age or less (2077 vs. 2627 ng/ml, p=0.022) whereas they were not 
statistically significant in neonates with MBL mutations (214 vs. 440 ng/ml, p=0.43). 
Interestingly, the rate of change of MBL levels between the first and subsequent samples 
was marginally influenced by gestational age at birth during the first week, tending to be 
larger in neonates with lower gestational age (+82 ng/ml/day p=0.12). MBL levels in
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WT neonates bom at less than 28 weeks therefore reached those bom at greater than 28 
weeks at 4 weeks postpartum (3900 vs. 3956 ng/ml, p=0.84).
The difference in baseline MBL level between neonates with very low birth weight 
(<1500 g) and the others were not significant either in WT (p=0.73) or neonates with 
variant alleles (p=0.57). However in WT neonates baseline MBL levels were 
significantly lower in neonates with a birth weight < lOOOg (2099 vs. 2654 ng/ml, 
p=0.015), or with gestational age < 28 weeks. This effect was not observed in neonates 
with MBL mutations (216 vs. 441 ng/ml, p=0.43). As with gestational age, the rate of 
change of MBL levels between the first and subsequent samples was marginally 
influenced by birth weight (+62 ng/ml/d, p=0.23).
The independent effects of each variable were not distinguishable because birth weight 
and gestational age at birth were too highly correlated (r=0.83, p<0.0001).
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Figure 4.1: MBL levels in neonates with a wild-type MBL genotype in relation to postnatal age. The box plots show
MBL levels (ng/ml) for gestational ages (<28 weeks and >28 weeks) and birth weight (<1000g and >1000g). The first sample 
was significantly lower than the three subsequent samples for all gestational ages and birth weights (p=0.001). Outliers are 
shown as black dots.
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Figure 4.2 MBL levels in neonates with MBL variant alleles in relation to postnatal age. The box plots show MBL 
levels (ng/ml) for gestational ages (<28 weeks and >28 weeks) and birth weight (<1000g and >1000g). The first sample was 
significantly lower than the three subsequent samples for all gestational ages and birth weights (p=0.01).
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4.4.5 Risk of sepsis in relation to MBL phenotype, birth weight and 
gestational age
One hundred twenty neonates with known MBL genotype and MBL levels from the first 
3 days of life were analyzed further to assess the risk of sepsis in preterm neonates. 
From this group, 37 (31%) had a definitive sepsis (confirmed positive blood culture). 45 
% of positive blood cultures occurred within the first week of life. Neonates with a birth 
weight <1000 g had a higher risk of sepsis (54% vs. 22%, OR=4.2, p<0.0001) as well as 
those with < 28 wks of gestational age at birth (55% vs. 23%, OR=4.0, p< 0.001). 52% 
of neonates with an MBL level at birth of < 400 ng/ml (n=27) (first quartile of the 
distribution), had sepsis compared to 26%, 0R=3.1, p=0.01 in neonates with an MBL 
levels of greater than 400ng/ml.
The independent effect of birth weight, gestational age at birth when adjusting for low 
MBL level (^OOng/ml) through a multivariable logistic regression was performed 
(Table 4.10). MBL level and birth weight (< lOOOg) and gestational age (<28 wks) 
remained independently associated with the risk of sepsis. The probability of sepsis in a 
neonate of < 28 weeks GA or < lOOOg BW with MBL levels < than 400ng/ml was 70%. 
With MBL levels above 400ng/ml the risk of sepsis was 47% in both groups. Again 
because of the high correlation between birth weight and gestational age their 
independent effect could not be checked.
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Table 4.10 Risk of definitive sepsis depending on MBL genotype, phenotype, 
gestational age (GA) and birth weight (BW). Analysis performed by Uni- and 
Multivariable analysis. Odds ration (CD) and p value.
Factor Patients
(n=120)
Definitive
sepsis
(%)
Unadjusted
effect
Multivariable 
model 1
Multivariable 
model 2
MBL
Genotype (p=0.33) - -
A/A 77 29% 1
A/0 and 0 /0 43 37% 1.48
MBL levels (p=0.01) (p=0.03) (p=0.04)
>400 ng/ml 93 26% 1 1 1
<400 ng/ml 27 52% 3.1 2.9 2.7
BW (p=0.0006) (p=0.001)
>1000g 83 22% 1 1 -
<1000 g 37 54% 4.2 4.1
GA (p<0.001) (p<0.003)
>28 wks 87 23% 1 - 1
wks 33 55% 4.0 3.7
In table 4.10 two separate multiple logistic regression models were presented, model 1 
adjusted for birth weight (BW) and the model 2 adjusted for gestational age (GA). These 
two variables BW and GA were strongly correlated leading to collinearity issue when 
adjusting for both in the same model.
The MBL cut-off of 400 ng/ml (first quartile of the distribution), threshold of 400 ng/ml 
was defined a priori according to biological/ clinical hypotheses. First, in the a study of
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MBL levels and genotypes from over 500 children from the AVON longitudinal study of 
parents and children, individuals who were either YO/YO  or XA/YB or XA/YC  all had 
levels of less than 400ng/ml (unpublished data). Second, in previous studies on MBL it 
was found that MBL levels below 400ng/ml did not activate complement binding and 
did not enhance MBL-mediated opsonophagocytosis (Neth at al., 2002).
4.4.6 MBL status and duration of antibiotic therapy
In the British neonates, the duration of antibiotic therapy used in the first 30 days of life 
was recorded. 47 neonates had both MBL genotype and phenotype measured in the first 
3 days of life. Nineteen neonates received more than 10 days of antibiotics. Of these, 10 
had one or more variant alleles. Of the 28 who received antibiotics for 10 days or less, 
only 9 had AJO or 0 /0  genotypes (p=0.08). When antibiotic duration was related to 
MBL status, as determined by phenotype (Figure 4.3), median MBL levels were found 
to be significantly lower in patients treated with antibiotics for more than 10 days as 
compared to neonates receiving antibiotics for 10 days or less (422 ng/ml V5 1618 ng/ml, 
p=0.02), (Figure 4.3). Three of the 9 neonates who had a WT genotype and who 
received more than 10 days of antibiotics had levels of less than 1000 ng/ml. This was 
double the proportion (3 out of 19) of WT neonates with MBL levels of lOOOng/ml or 
less and who received antibiotics for less than 10 days.
109
5 0 0 0 .0 0 -
4 0 0 0 .0 0 -
co
73 3 0 0 0 .0 0 -
U)
>  2000.00 -
1000. 00 -
0.00-
< 1 0  days or =10 days >10 days
Antibiotic therapy group
Figure 4.3 MBL levels in therapy groups (cut off 10 days) (p=0.02, Mann-Witney 
test). Box-whisker plots of MBL serum concentrations (ng/ml) in preterm British 
neonates (1-3 days of life). The boxed area represents 50% of values. The thick line 
inside the box represents the median value. Whiskers are 10-th and 90-th percentiles. 
Outliers are open circles.
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4.5 DISCUSSION
In the present study we have investigated the potential role of MBL in determining the 
susceptibility of preterm neonates to sepsis. The most important finding was that VLBW 
neonates, particularly ELBW who were MBL deficient were more likely to suffer from 
sepsis. This is the first study to look in detail at MBL status (genotype/ phenotype) and 
susceptibility to infection in premature neonates, and provides support for the view that 
MBL is important in protecting neonates from infection.
The clinical effect of MBL deficiency was most apparent in the VLBW neonates 
including 45 ELBW neonates. Of the 95 neonates classified as VLBW, 69 had a septic 
episode. This occurred in 84% of neonates with variant alleles and 67% in the WT 
population. This significant increase in sepsis was not obviously due to a difference in 
the type of micro-organisms isolated from the neonates. Of the 47 positive blood 
cultures, 42 were fi*om VLBW neonates. 53% of VLBW neonates with variant alleles 
had a positive blood culture compared with 39% in the WT VLBW population. This just 
failed to reach significance but indicates that one potential mechanism for why neonates 
with variant alleles have more sepsis is because they are more susceptible to bacterial 
invasion. Such an explanation is thought to explain why MBL deficient mice are more 
likely to succumb to Staphylococcus aureus and Pseudomonas aeruginosa infections 
(Shi et al, 2004; Moller-Kristensen et al, 2006). A recent paper has also found an 
association between low MBL levels and an increased risk of sepsis (De Benedetti at al, 
2007). In this study nearly half of the positive blood cultures grew Klebsiella
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pneumoniae. In contrast, the rate of proven sepsis to non-CONS organisms in our study 
was low. This probably reflects differences in environment, supportive care practise and 
possibly in the volumes of blood sampled. However it is also possible that the 
difference between the WT and variant MBL populations is not just the rate of sepsis but 
also the host response to a bacterial challenge. In a recent study of children with 
systemic inflammatory response syndrome (SIRS), MBL deficiency was highly 
correlated with the development of SIRS (Tidier et al, 2004). This was not apparently 
due to an increase in invasive bacterial infections. It has now been established that MBL 
can modulate cytokine production in vitro and in vivo (Jack et al, 2001; Shi et al, 2004; 
Mol 1er- Kristensen et al, 2006) and this may influence the response of neonates to even 
minor infections. Further studies are required to establish definitively why MBL 
deficiency predisposes preterm neonates to sepsis.
In previous studies, gestational age and birth weight were found to markedly influence 
MBL levels (Lau et al, 1995; Hilgendorff et al, 2005; Frakking et al., 2006). The effect 
of gestational age or birth weight on MBL levels was seen only in wild type neonates. 
As figures 4.1 and 4.2 demonstrate, MBL levels were lower in neonates with variant 
alleles, low birth weight or low gestational age at birth. By far the most important 
influence on MBL levels was postnatal age. In the first three days of life, all neonates, 
including those with variant alleles, had significantly less MBL than at the three 
subsequent time points analysed in this study. MBL is synthesised by hepatocytes and 
appears to show a similar developmental pattern to that of other proteins synthesised by 
the liver (Manco-Johnson 2005). The significance of this finding, also highlighted by 
Frakking, is that even neonates with a WT genotype may be deficient in MBL at birth
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(Frakking et al, 2006). This would increase the number of premature neonates who are 
phenotypically MBL deficient at birth above the 35% who had variant alleles. The 
clinical effect of low MBL levels within the WT neonates, who are in effect MBL 
deficient, was demonstrated in the analysis of antibiotic usage in the UK cohort. 6 of the 
28 WT neonates in whom data was also available on antibiotic usage, had MBL levels of 
less than 1000 ng/ml. Half of these received more than 10 days of antibiotics. We 
consider antibiotic usage to be a marker of sepsis, as a course of at least 10 days of 
antibiotics was always administered for proven or presumed sepsis in the UK cohort. As 
such it would appear that low levels of MBL even within the WT population can 
predispose preterm neonates to sepsis.
The main findings of this study were that the combination of MBL deficiency and 
prematurity renders such neonates particularly susceptible to sepsis. The study only 
monitored neonatal infections throughout the first month of life. Clearly VLBW 
neonates may still be cared for in the neonatal intensive care unit after this time and will 
therefore still be susceptible to infections. Genetic MBL deficiency may still be 
important in this population. However, an analysis of septic episodes within the two 
neonatal units involved in this study shows that about half of septic episodes occurred 
within the first week of life. This may be at least partly due to our observation that 
around half of newborn babies will also be MBL deficient. MBL will become available 
as a therapeutic agent in the near future and fi'om our results, may be a useful adjunct to 
the care of VLBW neonates (Valdimarsson et al, 2003; 2004).
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CHAPTER 5
GENERAL DISCUSSION
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The two studies presented in this thesis provide fiirther evidence that MBL is a 
determinant of infectious susceptibility and severity.
5.1 THE ROLE OF MBL IN HIV INFECTION
The results presented in chapter 3 showed that genetic MBL deficiency was found to be 
less common (23%) in HIV infected children in our cohort from GOSH (79 % were of 
Sub-Saharan origin, mean age 8.9 years) than in previously published African and UK 
cohorts of children and adults (Lipscombe et al, 1996; Mead et al, 2003; Mombo et al, 
2003; Garred et al, 2003; Kristensen et al, 2004). This finding was unexpected. From 
the previous literature (Lipscombe et al, 1996; Garred et al, 2003; Kristensen et al, 
2004), we expected to find an increase in MBL deficiency in the HIV population. Taken 
at face value, this finding could indicate that the high rate of MBL deficiency in African 
populations (Lipscombe et al, 1996; Mead et al, 2003; Mombo et al, 2003; Garred et 
al, 2003; Kristensen et al, 2004) could be protective against this infection. However we 
think this is unlikely for two reasons. Firstly, this finding differs from previous studies in 
which MBL deficiency was found to be higher in HIV infected individuals. Secondly, 
we found a relationship between high rates of MBL deficiency in HIV patients with 
more severe disease, as indicated by CD4+ T cell counts, and in a small cohort of 
LTNP’s. We conclude that MBL deficiency predisposes to HIV infection and more 
severe disease and as such the studied cohort had fewer MBL deficient individuals 
because of the death of children in the pre-HART era.
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There were a number of potential problems with this study, which must be considered. 
Firstly, there was no ethnically matched control group. This makes interpretation of our 
data very difficult. Secondly, the study was cross-sectional and performed within the era 
of HAART. This also complicates the analyses. Thirdly, the study was performed in 
children and most published studies have been from adult cohorts. In spite of these 
potential problems interpretations of our data are consistent with the limited data 
published in children. MBL variant alleles were significantly more frequent in HIV 
infection in perinatally exposed Brazilian children than in unexposed uninfected children 
(Boniotto et al, 2003). MBL gene polymorphisms in promoter and exon-1 region were 
also correlated with HIV disease progression (Amaroso et al, 1999; Boniotto et al, 
2000) and children with rapidly progressing disease were more likely to have MBL 
variant alleles (codon 54) (Amaroso et al, 1999).
It is difficult to see how this data will impact on the management of children with HIV 
infection. It may allow for the identification of individuals who may not cope well with 
ART interruption or even moderate disease. It is unlikely that MBL would be useful 
therapeutically. This is because it would probably have to be given very frequently as 
the MBL half life is short and also MBL appears to have limited antiviral activity in the 
physiological doses ranges (Ying et al, 2004).
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5.1.1 MBL and other viral infections
MBL has been shown to bind to a number of viruses including Influenza, Hepatitis B 
and C and SARS (Thielens et al, 2002). However as with HIV binding will not always 
indicate a role in the clinical settings. The role of MBL in chronic hepatitis B and C viral 
infections has been investigated in adults’ populations (Thomas et al, 1996; Yuen et al., 
1999; Sasaki et al, 2000; Kilpatrick et al, 2003; Thio et al, 2005). An association of 
exon-1 MBL gene with persistent HBV infection and progression of HBV and HCV 
disease has been found (Thomas et al, 1996; Yuen et al, 1999, Sasaki et al, 2000). 
Several studies have suggested that low-MBL producing genotypes are associated with a 
poor response to interferon treatment in chronic hepatitis C patients (Matsushita et al, 
1998; Sasaki et al, 2000).
5.2 THE ROLE OF MBL IN NEONATAL INFECTION
Several genes have been examined to ascertain if they play a role in the inflammatory 
response and in sepsis. These include the genes for tumor necrosis factor (TNF)-alpha, 
TNF-beta, the interleukin (IL)-l receptor antagonist, heat shock protein (hsp70), IL-6, 
IL-10, CD-14, Toll-like receptors: TLR-2, TLR-4 , and N0D2 (Weitkamp et al, 2000; 
Holmes et al, 2003; Levy et al, 2004; Ahrens et al, 2004). However, to date only one 
such study has been performed in preterm neonates. 356 VLBW neonates were 
genotyped for MBL variants, the IL-6-174 G/C polymorphism, CD 14-159 T mutation, 
TLR4-896G mutation and NOD2-3020 ins C-mutation. Sepsis in VLBW infants was
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defined as blood culture-proven sepsis (Ahrens et al, 2004). VLBW neonates who did 
not carry any of the mutations had a lower frequency of blood culture proven sepsis than 
neonates who did carry mutations. Carries of the homozygous IL-6-174 G mutation and 
carriers of the NOD2-3020ins C mutation had a higher rate of sepsis than non carriers. 
Within, the limits of the study size (n=50), the MBL B/C/D alleles analyzed did not 
appear to substantially influence the risk of neonatal sepsis (Ahrens et al, 2004).
The study presented in this thesis differed from the Ahrens study described above. 
Information on both MBL genotype and phenotype were obtained as well as the rates of 
sepsis in preterm neonates within a wide range of gestational age (24-36 weeks of 
gestation) and birth weight (510-2958 grams). In addition the study included almost 
three times as many patients as the Ahrens study.
The gene frequencies of MBL-2 gene polymorphisms in exon-1 region (both 
heterozygous and homozygous) investigated in our cohort of neonates (41 % in the UK 
cohort; 33 % in the Polish cohort) were in keeping with the frequencies previously 
published in other UK cohorts (Mead et al, 1997; Roy et al, 2002). There was no 
obvious association between MBL genotype and risk of prematurity. The presence of 
polymorphisms in the MBL-2 gene appeared to be associated with the development of 
sepsis in VLBW neonates. 84 % of genetically MBL deficient VLBW neonates were 
septic (blood culture proven and clinically presumed sepsis) compared to 66% septic 
neonates with a wild-type MBL -2 genotype. Low MBL levels through prematurity, and 
not only through MBL variant alleles, also contributed to the population of neonates who 
were MBL deficient. This was particularly marked in ELBW neonates and or gestation
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of < 28 weeks. These findings were in accordance with the two recently published 
studies (Hilgendorff et al, 2005; Frakking et al, 2006).
MBL deficiency as detected by genotype and phenotype predisposed VLBW neonates to 
sepsis. The risk of infection was particularly high (45%) in the first week of life. This 
corresponds to the period in which MBL levels were at their lowest. Development has 
been shown to be a significant influence on the production of components of the MBL- 
lectin and associated pathways. MBL appear to show a similar developmental pattern to 
that of other proteins synthesized by the liver (Manco-Johnson, 2005; Nava et al, 2005). 
MASP-1 and MASP-2 mRNA was expressed as early as embryonic day 12.5. Its 
expression progressively increased during development, peaked around birth and 
slightly declined in adult stages. The expression profiles of Ficolin A in the embryo and 
liver closely resembled that of the MASPs (Liu et al, 2005).
Further studies are required to establish the significance of MBL deficiency in 
predisposing neonates to infection. Further studies are also required to explore the 
impact of the entire MBL-lectin pathway including its associated serine proteases, 
MASPs. Recently, a genetically determined deficiency of MASP-2 was described 
(Stengaard-Pedersen et al, 2003). The mutation of a single nucleotide leads to an ASP- 
Gly exchange in CUB 1 domain that renders MASP-2 incapable of binding to MBL. The 
consequences of MASP-2 deficiency might be more severe since MASP-2 mediates the 
activation of complement through MBL. Therefore it would be especially relevant to 
determine whether low serum levels of MASP-2 correlate with susceptibility to sepsis in 
neonates. This analysis is ongoing and the results will be known in near future.
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The presence of MBL variant alleles is known to be associated with the development of 
sepsis in adults with systemic inflammatory response syndrome (SIRS; Garred et al, 
2003). A paediatric study implicating MBL deficiency with increased incidence and 
severity of SIRS in MBL-deficient subjects has also been reported (Fidler et a l, 2004). 
Although the pathophysiology of SIRS and sepsis is very complex, it has been shown 
that genetic factors of importance for the inflammatory response such as polymorphisms 
associated with regulation of the expression of TNF-a and IL-1 receptor antagonist gene 
may be associated with susceptibility to and outcome of sepsis (Mira et al, 1999; 
Amalich et al, 2002). It has now been established that MBL can modulate cytokine 
production and this may influence the response to infection (Jack et al, 2001). 
Moreover, genetic complement deficiency and complement depletion have been shown 
to be beneficial in animal models of complement dependent inflammation (Czermak et 
al, 1999). Thus, complement and, probably MBL may play different roles during the 
course of sepsis and systemic inflammatory response syndrome (SIRS). The factors that 
modulate and regulate MBL levels remain unclear and require further research.
Future studies investigating other genes involved in innate immunity such as: TLRs, 
NOD-2, Interleukin-6 (IL-6), and Defensins should provide a more comprehensive 
understanding of the role of these genes in the susceptibility and outcome of sepsis in 
preterm neonates. The application of molecular methods to identify neonates with 
genetic variants (Kilpinen et al, 2001; Gibot et al, 2002; Lorenz et al, 2002) would 
help to identify which neonates are at particular risk of sepsis and may benefit from 
adjunctive /novel therapies.
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From our results it would appear that MBL can protect VLBW neonates from sepsis. 
The potential therapeutic use of supplementing low MBL levels either by plasma- 
derived or recombinant protein in various clinical conditions such as VLBW preterm 
neonates and during sepsis may provide a promising approach towards decreasing 
mortality and morbidity in this population (Valdimarsson et al, 1998; Vorup-Jensen et 
al, 2001).
In summary, the results presented in this thesis provide support for the view that MBL 
plays a role in neonatal infection and in paediatric HIV disease. Further work is needed 
before the clinical significance of these findings is known and before therapeutic use of 
MBL in these populations of patients can be investigated.
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